Current awareness: Pharmacoepidemiology and drug safety
Identifieur interne : 001B59 ( Istex/Corpus ); précédent : 001B58; suivant : 001B60Current awareness: Pharmacoepidemiology and drug safety
Auteurs :Source :
- Pharmacoepidemiology and Drug Safety [ 1053-8569 ] ; 2005-08.
English descriptors
- Teeft :
- Acad, Acad dermatol, Acta, Adverse effects, Allergy, Allergy asthma immunol, Asthma, Canc, Cardiol, Cardiovascular, Case report, Case reports, Clin, Clin drug, Clin pharmacol, Clin psychiatry, Clin psychopharmacol, Coll, Copyright, Current awareness, Dept, Dept clin pharmacol, Dept dermatol, Dept neurol, Dept pediat, Dept pharm, Dept psychiat, Dept rheumatol, Dermatol, Diabetes mellitus, Drug safety, Epidemiol, Gastroenterol, Heidelberg, Heparin, Hlth, Hosp, Immunol, Inhibitor, Inst, John wiley sons, Joint bone spine, Natl, Nephrol, Nephrol dial transplant, Neurol, Nijmegen, Olanzapine, Oncol, Ophthalmol, Pediat, Pediatr, Pharm, Pharmacoepidemiology, Pharmacokinetics, Pharmacol, Pharmacother, Psychiat, Psychopharmacol, Publ, Renal, Rheumatol, Scand, Serv, Suppl, Surg, Thrombocytopenia, Toxicity, Transplant, Univ, Urol, Vaccine, Weight gain.
Abstract
In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 20 sections: 1 Books, Reviews & Symposia; 2 General; 3 Anti‐infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non‐steroidal Anti‐inflammatory Agents; 7 CNS Agents; 8 Anti‐neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator‐Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti‐inflammatory Agents ‐ Steroidal; 19 Teratogens/fetal exposure; 20 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted.
Url:
DOI: 10.1002/pds.1030
Links to Exploration step
ISTEX:2373BA77F1E26EB00479968C030A9652218EB467Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Current awareness: Pharmacoepidemiology and drug safety</title></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:2373BA77F1E26EB00479968C030A9652218EB467</idno><date when="2005" year="2005">2005</date><idno type="doi">10.1002/pds.1030</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-FRP40FW4-3/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">001B59</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001B59</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Current awareness: Pharmacoepidemiology and drug safety</title></analytic><monogr></monogr><series><title level="j" type="main">Pharmacoepidemiology and Drug Safety</title><title level="j" type="alt">PHARMACOEPIDEMIOLOGY AND DRUG SAFETY</title><idno type="ISSN">1053-8569</idno><idno type="eISSN">1099-1557</idno><imprint><biblScope unit="vol">14</biblScope><biblScope unit="issue">8</biblScope><biblScope unit="page" from="i">i</biblScope><biblScope unit="page" to="xii">xii</biblScope><biblScope unit="page-count">12</biblScope><publisher>John Wiley & Sons, Ltd.</publisher><pubPlace>Chichester, UK</pubPlace><date type="published" when="2005-08">2005-08</date></imprint><idno type="ISSN">1053-8569</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1053-8569</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Acad</term><term>Acad dermatol</term><term>Acta</term><term>Adverse effects</term><term>Allergy</term><term>Allergy asthma immunol</term><term>Asthma</term><term>Canc</term><term>Cardiol</term><term>Cardiovascular</term><term>Case report</term><term>Case reports</term><term>Clin</term><term>Clin drug</term><term>Clin pharmacol</term><term>Clin psychiatry</term><term>Clin psychopharmacol</term><term>Coll</term><term>Copyright</term><term>Current awareness</term><term>Dept</term><term>Dept clin pharmacol</term><term>Dept dermatol</term><term>Dept neurol</term><term>Dept pediat</term><term>Dept pharm</term><term>Dept psychiat</term><term>Dept rheumatol</term><term>Dermatol</term><term>Diabetes mellitus</term><term>Drug safety</term><term>Epidemiol</term><term>Gastroenterol</term><term>Heidelberg</term><term>Heparin</term><term>Hlth</term><term>Hosp</term><term>Immunol</term><term>Inhibitor</term><term>Inst</term><term>John wiley sons</term><term>Joint bone spine</term><term>Natl</term><term>Nephrol</term><term>Nephrol dial transplant</term><term>Neurol</term><term>Nijmegen</term><term>Olanzapine</term><term>Oncol</term><term>Ophthalmol</term><term>Pediat</term><term>Pediatr</term><term>Pharm</term><term>Pharmacoepidemiology</term><term>Pharmacokinetics</term><term>Pharmacol</term><term>Pharmacother</term><term>Psychiat</term><term>Psychopharmacol</term><term>Publ</term><term>Renal</term><term>Rheumatol</term><term>Scand</term><term>Serv</term><term>Suppl</term><term>Surg</term><term>Thrombocytopenia</term><term>Toxicity</term><term>Transplant</term><term>Univ</term><term>Urol</term><term>Vaccine</term><term>Weight gain</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 20 sections: 1 Books, Reviews & Symposia; 2 General; 3 Anti‐infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non‐steroidal Anti‐inflammatory Agents; 7 CNS Agents; 8 Anti‐neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator‐Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti‐inflammatory Agents ‐ Steroidal; 19 Teratogens/fetal exposure; 20 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted.</div></front></TEI><istex><corpusName>wiley</corpusName><keywords><teeft><json:string>univ</json:string><json:string>clin</json:string><json:string>hosp</json:string><json:string>pharmacol</json:string><json:string>case report</json:string><json:string>inst</json:string><json:string>pharmacoepidemiology</json:string><json:string>pharm</json:string><json:string>pharmacother</json:string><json:string>hlth</json:string><json:string>psychiat</json:string><json:string>dermatol</json:string><json:string>neurol</json:string><json:string>drug safety</json:string><json:string>serv</json:string><json:string>surg</json:string><json:string>coll</json:string><json:string>dept</json:string><json:string>nephrol</json:string><json:string>clin pharmacol</json:string><json:string>immunol</json:string><json:string>dept psychiat</json:string><json:string>john wiley sons</json:string><json:string>epidemiol</json:string><json:string>cardiol</json:string><json:string>copyright</json:string><json:string>pediatr</json:string><json:string>ophthalmol</json:string><json:string>gastroenterol</json:string><json:string>allergy</json:string><json:string>natl</json:string><json:string>current awareness</json:string><json:string>acta</json:string><json:string>dept neurol</json:string><json:string>oncol</json:string><json:string>scand</json:string><json:string>psychopharmacol</json:string><json:string>pharmacokinetics</json:string><json:string>thrombocytopenia</json:string><json:string>rheumatol</json:string><json:string>pediat</json:string><json:string>toxicity</json:string><json:string>acad</json:string><json:string>suppl</json:string><json:string>dept dermatol</json:string><json:string>canc</json:string><json:string>clin psychiatry</json:string><json:string>case reports</json:string><json:string>publ</json:string><json:string>heparin</json:string><json:string>urol</json:string><json:string>olanzapine</json:string><json:string>nijmegen</json:string><json:string>allergy asthma immunol</json:string><json:string>diabetes mellitus</json:string><json:string>nephrol dial transplant</json:string><json:string>acad dermatol</json:string><json:string>weight gain</json:string><json:string>dept clin pharmacol</json:string><json:string>clin psychopharmacol</json:string><json:string>cardiovascular</json:string><json:string>asthma</json:string><json:string>vaccine</json:string><json:string>transplant</json:string><json:string>dept rheumatol</json:string><json:string>dept pharm</json:string><json:string>clin drug</json:string><json:string>adverse effects</json:string><json:string>joint bone spine</json:string><json:string>dept pediat</json:string><json:string>renal</json:string><json:string>inhibitor</json:string><json:string>heidelberg</json:string><json:string>cent hosp</json:string><json:string>univ texas</json:string><json:string>selective serotonin reuptake inhibitors</json:string><json:string>mcgill univ</json:string><json:string>univ calif</json:string><json:string>dept obstet gynecol</json:string><json:string>harvard univ</json:string><json:string>brigham womens hosp</json:string><json:string>anesth analg</json:string><json:string>dept anaesthesia</json:string><json:string>univ kentucky</json:string><json:string>erectile dysfunction</json:string><json:string>quetiapine treatment</json:string><json:string>arthritis rheum</json:string><json:string>thromb haemost</json:string><json:string>dept pharm serv</json:string><json:string>adverse events</json:string><json:string>coll pharm</json:string><json:string>transplant proc</json:string><json:string>univ heidelberg</json:string><json:string>risk factors</json:string><json:string>anderson canc</json:string><json:string>dept gastroenterol</json:string><json:string>dept pharm practice</json:string><json:string>acta psychiatr scand</json:string><json:string>special issue</json:string><json:string>psychiatry</json:string><json:string>systematic review</json:string><json:string>hlth care</json:string><json:string>healthy subjects</json:string><json:string>univ vienna</json:string><json:string>brit columbia</json:string><json:string>clin pharmacol toxicol</json:string><json:string>univ zurich hosp</json:string><json:string>general practice</json:string><json:string>neurol serv</json:string><json:string>drug combinations</json:string><json:string>cardiovascular risk</json:string><json:string>intens care unit</json:string><json:string>retrospective evaluation</json:string><json:string>renal disease</json:string><json:string>influenza vaccination</json:string><json:string>drug reactions</json:string><json:string>immune thrombocytopenia</json:string><json:string>sudden death</json:string><json:string>univ wurzburg</json:string><json:string>dept nephrol</json:string><json:string>atypical antipsychotics</json:string><json:string>healthy volunteers</json:string><json:string>wayne state univ</json:string><json:string>adverse reactions</json:string><json:string>dept surg</json:string><json:string>publ hlth</json:string><json:string>cornell univ</json:string><json:string>inhaled corticosteroids</json:string><json:string>univ nottingham</json:string><json:string>depressive agents</json:string><json:string>successful treatment</json:string><json:string>chronic hepatitis</json:string><json:string>auckland city hosp</json:string><json:string>sturkenboom mcjm</json:string><json:string>liver transplant</json:string><json:string>psychotropic drugs</json:string><json:string>drug interaction</json:string><json:string>gastroenterol clin biol</json:string><json:string>crit care</json:string><json:string>dept cardiol</json:string><json:string>probable interaction</json:string><json:string>fundam clin pharmacol</json:string><json:string>thomas hosp</json:string><json:string>case series</json:string><json:string>cancer pain</json:string><json:string>dept ophthalmol</json:string><json:string>wahringer gurtel vienna</json:string><json:string>holcombe blvd</json:string><json:string>glibenclamide combination tablets</json:string><json:string>acta neurol scand</json:string><json:string>tolerability profile</json:string><json:string>acta anaesthesiol scand</json:string><json:string>intrathecal midazolam</json:string><json:string>west drayton</json:string><json:string>wake forest univ</json:string><json:string>winston salem</json:string><json:string>harrier house</json:string><json:string>dept clin expt</json:string><json:string>efficacy study</json:string><json:string>contact dermatitis</json:string><json:string>rheumatoid arthritis</json:string><json:string>orsola hosp</json:string><json:string>univ helsinki</json:string><json:string>univ bologna</json:string><json:string>botulinum toxin type</json:string><json:string>albert schweitzer</json:string><json:string>child adolesc psychopharmacol</json:string><json:string>clin pharmacokinet</json:string><json:string>hong kong</json:string><json:string>chapel hill</json:string><json:string>auburn univ</json:string><json:string>support care cancer</json:string><json:string>walker bldg</json:string><json:string>univ pittsburgh</json:string><json:string>health syst pharm</json:string><json:string>disease patients</json:string><json:string>columbia univ</json:string><json:string>coll phys surg</json:string><json:string>pediatr blood cancer</json:string><json:string>stanford univ</json:string><json:string>clin oncol</json:string><json:string>arch ophthalmol</json:string><json:string>venous thromboembolism</json:string><json:string>arch intern</json:string><json:string>liver injury</json:string><json:string>atopic dermatitis</json:string><json:string>reviews symposia</json:string><json:string>aliment pharmacol</json:string><json:string>cardiovascular safety</json:string><json:string>urol suppl</json:string><json:string>pediatr ophthalmol strabismus</json:string><json:string>hormone replacement therapy</json:string><json:string>leuprolide acetate therapy</json:string><json:string>gastric drugs</json:string></teeft></keywords><articleId><json:string>PDS1030</json:string></articleId><arkIstex>ark:/67375/WNG-FRP40FW4-3</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>bibliography</json:string></originalGenre><abstract>In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 20 sections: 1 Books, Reviews & Symposia; 2 General; 3 Anti‐infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non‐steroidal Anti‐inflammatory Agents; 7 CNS Agents; 8 Anti‐neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator‐Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti‐inflammatory Agents ‐ Steroidal; 19 Teratogens/fetal exposure; 20 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted.</abstract><qualityIndicators><score>8.824</score><pdfWordCount>12475</pdfWordCount><pdfCharCount>77231</pdfCharCount><pdfVersion>1.3</pdfVersion><pdfPageCount>12</pdfPageCount><pdfPageSize>595 x 842 pts (A4)</pdfPageSize><pdfWordsPerPage>1040</pdfWordsPerPage><pdfText>true</pdfText><refBibsNative>true</refBibsNative><abstractWordCount>152</abstractWordCount><abstractCharCount>1082</abstractCharCount><keywordCount>0</keywordCount></qualityIndicators><title>Current awareness: Pharmacoepidemiology and drug safety</title><genre><json:string>other</json:string></genre><host><title>Pharmacoepidemiology and Drug Safety</title><language><json:string>unknown</json:string></language><doi><json:string>10.1002/(ISSN)1099-1557</json:string></doi><issn><json:string>1053-8569</json:string></issn><eissn><json:string>1099-1557</json:string></eissn><publisherId><json:string>PDS</json:string></publisherId><volume>14</volume><issue>8</issue><pages><first>i</first><last>xii</last><total>12</total></pages><genre><json:string>journal</json:string></genre><subject><json:item><value>Current Awareness</value></json:item><json:item><value>Current Awareness</value></json:item></subject></host><namedEntities><unitex><date><json:string>7-11-23</json:string><json:string>2005</json:string><json:string>2002</json:string><json:string>3-1-1</json:string></date><geogName><json:string>Rio Grande</json:string><json:string>Isar</json:string><json:string>Lake City</json:string><json:string>Beach Gardens</json:string></geogName><orgName><json:string>Kuwait Univ, Fac Med, Dept Surg, Div Opathalmol, POB</json:string><json:string>Montenegro, Yugoslavia</json:string><json:string>Anal Grp Inc</json:string><json:string>Natl Taiwan Univ Hosp, Department Emergency Med</json:string><json:string>Gamble Pharmaceut Co</json:string><json:string>Denver, Co</json:string><json:string>Sons, Ltd.</json:string><json:string>Radiopharm</json:string><json:string>Lilly Corp</json:string><json:string>Biochem</json:string><json:string>Pfizer Inc</json:string><json:string>Georgia Ave NW, Washington, DC</json:string><json:string>Singapore, Rep Singapore</json:string><json:string>Mexico City, DF, Mexico</json:string><json:string>Beth Israel Med Ctr, Dept Internal Med, Div Clin Immunol</json:string><json:string>Pathobiochem</json:string><json:string>Sons, Ltd</json:string><json:string>US/FDA, Division Drug Risk Evaluation, HFD</json:string><json:string>US/FDA, Off Drug Safety, Ctr Drug Evaluat</json:string><json:string>Singapore Eye Res Inst</json:string><json:string>US/FDA, Ctr Biol Evaluat</json:string><json:string>Dev Ltd</json:string><json:string>Univ Georgia, Coll Pharm, Athens, Ga</json:string><json:string>Schering Plough Corp</json:string><json:string>Eisenhower Army Med Ctr, Bldg</json:string></orgName><orgName_funder></orgName_funder><orgName_provider></orgName_provider><persName><json:string>Hadassah Med</json:string><json:string>Y. Shirasagi</json:string><json:string>Div Epidemiol</json:string><json:string>Kyle G. Univ</json:string><json:string>Div Infect</json:string><json:string>Pau Univ</json:string><json:string>P. Tayside</json:string><json:string>B. Kerala</json:string><json:string>R. Radboud</json:string><json:string>Alma Mater</json:string><json:string>Tom Baker</json:string><json:string>R. Hosp</json:string><json:string>K. Univ</json:string><json:string>Sydney St</json:string><json:string>Taylor D. Address</json:string><json:string>Ann Fr</json:string><json:string>Repolles</json:string><json:string>Eli Lilly</json:string><json:string>Ambroise Pare</json:string><json:string>Emmanuel Kaye</json:string><json:string>Rose St</json:string><json:string>F. Bahnhofstr</json:string><json:string>Gen Practice</json:string><json:string>King Khalid</json:string><json:string>M. Univ</json:string><json:string>La Laguna</json:string><json:string>Systematic</json:string><json:string>Contin</json:string><json:string>Gustave L Levy</json:string><json:string>Martino R. Stadtspital</json:string><json:string>Josef Schneider</json:string><json:string>P. Amer</json:string><json:string>J. Shenandoah</json:string><json:string>Div Nephrol</json:string><json:string>Ann Rheum</json:string><json:string>S. Hacettepe</json:string><json:string>Care</json:string><json:string>Cheng Kung</json:string><json:string>A. Belgian</json:string><json:string>Hong Kong</json:string><json:string>Cole Eye</json:string><json:string>Leo A. Univ</json:string><json:string>J. Rambam</json:string><json:string>Ann Oncol</json:string><json:string>Fox Chase</json:string><json:string>John Wiley</json:string><json:string>Wayne State</json:string><json:string>F. Pintelaan</json:string><json:string>Davies R. Univ</json:string><json:string>El Mouelhi</json:string><json:string>B. Univ</json:string><json:string>Georges Pompidou</json:string><json:string>Francis St</json:string><json:string>S. Univ</json:string><json:string>Francisco Miranda</json:string><json:string>Ann Thorac</json:string><json:string>A. Padiglione</json:string><json:string>R. Royal</json:string><json:string>Ronald McDonald</json:string><json:string>R. Beaumont</json:string><json:string>J. Inst</json:string><json:string>Mackenzie Bldg</json:string><json:string>Harrison Sch</json:string><json:string>T. Ishikawa</json:string><json:string>U. Univ</json:string><json:string>Div Cardiol</json:string><json:string>Giulio Cesare</json:string><json:string>R. McGill</json:string><json:string>B. Victor</json:string><json:string>Carl Neuberg</json:string><json:string>Gaston Ave</json:string><json:string>F. Univ</json:string><json:string>Semmelweis Univ</json:string><json:string>W. Univ</json:string><json:string>Gwendolen Rd</json:string><json:string>Erasmus Univ</json:string><json:string>CHU Jean</json:string><json:string>Sheng Li</json:string><json:string>Med</json:string><json:string>N. Sheppard</json:string><json:string>H. Univ</json:string><json:string>La Porte</json:string><json:string>O. Neurol</json:string><json:string>I. Dokuz</json:string><json:string>Antoine Beclere</json:string><json:string>T. Johnson</json:string><json:string>J. Grampian</json:string><json:string>Div Stroke</json:string><json:string>J. Univ</json:string><json:string>Edouard Herriot</json:string><json:string>S. Tech</json:string><json:string>D. Med</json:string><json:string>Address</json:string><json:string>J. Med</json:string><json:string>Paris Cad</json:string><json:string>P. Gen</json:string><json:string>Div Vasc</json:string><json:string>Rotterdam</json:string><json:string>M. Maltepe</json:string><json:string>Div Pharmacoepidemiol</json:string><json:string>Sinai Med</json:string><json:string>N. Royal</json:string><json:string>Blake Wilbur</json:string><json:string>Ann Arbor</json:string><json:string>Virginia Commonwealth</json:string><json:string>Vasco Quiroga</json:string><json:string>M. Showa</json:string><json:string>B. Mem</json:string><json:string>J. McGill</json:string><json:string>Div Gastroenterol</json:string><json:string>N. Roche</json:string><json:string>Auburn Univ</json:string><json:string>Francois Mitterand</json:string><json:string>Via Massarenti</json:string><json:string>Gen Univ</json:string><json:string>L. Royal</json:string><json:string>Roma Tor</json:string><json:string>Jean Monnet</json:string><json:string>P. Univ</json:string><json:string>Div Canc</json:string><json:string>Ram Manohar</json:string><json:string>Div Educat</json:string><json:string>Dr</json:string><json:string>Educ</json:string><json:string>Oswaldo Cruz</json:string><json:string>Gen Psychiatry</json:string><json:string>Div Digest</json:string><json:string>Remus C. Univ</json:string><json:string>La Crosse</json:string><json:string>J. Therabel</json:string><json:string>Marcos Hosp</json:string><json:string>Cohen D. Rijngeestgrp</json:string><json:string>CHU Rangueil</json:string><json:string>Shan Sth</json:string><json:string>Douglas Hosp</json:string><json:string>Div Cardiovasc</json:string><json:string>Div Clin</json:string><json:string>Giani G. Univ</json:string><json:string>Case</json:string><json:string>Ann Dermatol</json:string><json:string>Albert Schweitzer</json:string><json:string>La Jolla</json:string><json:string>G. McGill</json:string><json:string>Max Planck</json:string><json:string>Anderson Canc</json:string><json:string>Seng Hosp</json:string><json:string>R. Pontificia</json:string><json:string>Div Endocrinol</json:string><json:string>Gen Infirm</json:string><json:string>V. Univ</json:string><json:string>Div Child</json:string><json:string>N. Hop</json:string><json:string>P. Hop</json:string><json:string>Salvador Zubiran</json:string><json:string>Paul St</json:string><json:string>Ren Nutr</json:string><json:string>Leo Saignat</json:string><json:string>M. Argyll</json:string><json:string>G. Univ</json:string><json:string>B. Numune</json:string><json:string>Pedro Olaio</json:string><json:string>B. Brigham</json:string><json:string>Falcon State</json:string><json:string>Y. Yamanashi</json:string><json:string>Drake Univ</json:string><json:string>Ave Jean</json:string><json:string>Gen Hosp</json:string><json:string>Paul C. Prob</json:string><json:string>Ann Emerg</json:string><json:string>Div Emergency</json:string><json:string>I. Univ</json:string><json:string>Charles St</json:string><json:string>J. Harvard</json:string><json:string>Lucas C. Western</json:string><json:string>Thomas Jefferson</json:string><json:string>R. Natl</json:string></persName><placeName><json:string>Naples</json:string><json:string>Santander</json:string><json:string>PY</json:string><json:string>Maastricht</json:string><json:string>Minneapolis</json:string><json:string>Porto Alegre</json:string><json:string>Aberdeen</json:string><json:string>Verdun</json:string><json:string>Leiden</json:string><json:string>Lund</json:string><json:string>Stanford</json:string><json:string>Utrecht</json:string><json:string>San Miguel</json:string><json:string>Winnipeg</json:string><json:string>Fukuoka</json:string><json:string>Calgary</json:string><json:string>Berlin</json:string><json:string>Faubourg</json:string><json:string>Tel Aviv</json:string><json:string>Uppsala</json:string><json:string>Ankara</json:string><json:string>Birmingham</json:string><json:string>San Diego</json:string><json:string>Paris</json:string><json:string>Rochester</json:string><json:string>Bristol</json:string><json:string>Venezuela</json:string><json:string>Novi Sad</json:string><json:string>Cardiotoxicity</json:string><json:string>Miami</json:string><json:string>Switzerland</json:string><json:string>Marburg</json:string><json:string>Palermo</json:string><json:string>Columbia</json:string><json:string>Alicante</json:string><json:string>Hagen</json:string><json:string>Newcastle upon Tyne</json:string><json:string>Greece</json:string><json:string>St Thomas</json:string><json:string>Bordeaux</json:string><json:string>Kurashima</json:string><json:string>Nancy</json:string><json:string>Salamanca</json:string><json:string>Thailand</json:string><json:string>Munich</json:string><json:string>Innsbruck</json:string><json:string>Ghent</json:string><json:string>Udine</json:string><json:string>Antwerp</json:string><json:string>Edmonton</json:string><json:string>NY</json:string><json:string>Brescia</json:string><json:string>Australia</json:string><json:string>Heidelberg</json:string><json:string>Bern</json:string><json:string>Santa Clara</json:string><json:string>Lansing</json:string><json:string>Lipka</json:string><json:string>Korea</json:string><json:string>New Delhi</json:string><json:string>Verona</json:string><json:string>Grenoble</json:string><json:string>Seoul</json:string><json:string>Ulm</json:string><json:string>Poland</json:string><json:string>Brazil</json:string><json:string>Dakar</json:string><json:string>Mendoza</json:string><json:string>Albacete</json:string><json:string>Bangkok</json:string><json:string>Austria</json:string><json:string>Montreal</json:string><json:string>Pisa</json:string><json:string>Washington</json:string><json:string>Serbia</json:string><json:string>Bangor</json:string><json:string>Turin</json:string><json:string>Turkey</json:string><json:string>Sendai</json:string><json:string>Dunedin</json:string><json:string>Richmond</json:string><json:string>GA</json:string><json:string>Saudi Arabia</json:string><json:string>Taiwan</json:string><json:string>Sherbrooke</json:string><json:string>Canada</json:string><json:string>Genoa</json:string><json:string>Braga</json:string><json:string>DC</json:string><json:string>Houston</json:string><json:string>Nephrotoxicity</json:string><json:string>Niigata</json:string><json:string>Helsinki</json:string><json:string>Cardiff</json:string><json:string>St Lukes</json:string><json:string>NC</json:string><json:string>Greenland</json:string><json:string>SC</json:string><json:string>Nottingham</json:string><json:string>San Sebastian</json:string><json:string>Madrid</json:string><json:string>Rio de Janeiro</json:string><json:string>Newport</json:string><json:string>St Philibert</json:string><json:string>Dundee</json:string><json:string>Cincinnati</json:string><json:string>Jersey City</json:string><json:string>Seattle</json:string><json:string>Bologna</json:string><json:string>Haifa</json:string><json:string>Warsaw</json:string><json:string>China</json:string><json:string>Nijmegen</json:string><json:string>Vancouver</json:string><json:string>Toronto</json:string><json:string>Atlanta</json:string><json:string>Rotherham</json:string><json:string>Nantes</json:string><json:string>Los Angeles</json:string><json:string>USA</json:string><json:string>Athens</json:string><json:string>Japan</json:string><json:string>Jerusalem</json:string><json:string>Strasbourg</json:string><json:string>Brussels</json:string><json:string>Leeds</json:string><json:string>Vienna</json:string><json:string>Liverpool</json:string><json:string>Dijon</json:string><json:string>Barcelona</json:string><json:string>Basel</json:string><json:string>San Francisco</json:string><json:string>Dublin</json:string><json:string>Amsterdam</json:string><json:string>Auckland</json:string><json:string>Glasgow</json:string><json:string>Toulouse</json:string><json:string>New Zealand</json:string><json:string>Frankfurt</json:string><json:string>Rome</json:string><json:string>St Antoine</json:string><json:string>Chicago</json:string><json:string>Hashima City</json:string><json:string>Hashima</json:string><json:string>Patras</json:string><json:string>Murcia</json:string><json:string>Papsdorf</json:string><json:string>San Vicente</json:string><json:string>Portugal</json:string><json:string>Israel</json:string><json:string>York</json:string><json:string>St Radboud</json:string><json:string>St Michaels</json:string><json:string>Ottawa</json:string><json:string>Kuwait</json:string><json:string>Ireland</json:string><json:string>France</json:string><json:string>NJ</json:string><json:string>Quebec</json:string><json:string>St Elizabeths</json:string><json:string>Copenhagen</json:string><json:string>Greenville</json:string><json:string>Izmir</json:string><json:string>Bari</json:string><json:string>Hepatotoxicity</json:string><json:string>St Leonards</json:string><json:string>Indianapolis</json:string><json:string>Hungary</json:string><json:string>Italy</json:string><json:string>Braunschweig</json:string><json:string>Istanbul</json:string><json:string>Cleveland</json:string><json:string>Detroit</json:string><json:string>Sweden</json:string><json:string>Postgrad</json:string><json:string>Taipei</json:string><json:string>England</json:string><json:string>MN</json:string><json:string>Odense</json:string><json:string>Mainz</json:string><json:string>Zurich</json:string><json:string>Ulsan</json:string><json:string>Budapest</json:string><json:string>Lyon</json:string><json:string>Belgium</json:string><json:string>Auckland City</json:string><json:string>Kanazawa</json:string><json:string>Netherlands</json:string><json:string>Osaka</json:string><json:string>Tucson</json:string><json:string>Pau</json:string></placeName><ref_url></ref_url><ref_bibl><json:string>Walter Reed Army Med Ctr, Dept Internal Med, 6900</json:string><json:string>National Immunization Survey, 2001</json:string><json:string>Clinilabs Inc, 1090</json:string><json:string>Amylin Pharmaceut Inc, 9360</json:string></ref_bibl><bibl></bibl></unitex></namedEntities><ark><json:string>ark:/67375/WNG-FRP40FW4-3</json:string></ark><categories><wos><json:string>1 - science</json:string><json:string>2 - pharmacology & pharmacy</json:string></wos><scienceMetrix><json:string>1 - health sciences</json:string><json:string>2 - clinical medicine</json:string><json:string>3 - pharmacology & pharmacy</json:string></scienceMetrix><scopus><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Pharmacology (medical)</json:string><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Epidemiology</json:string></scopus><inist><json:string>1 - sciences appliquees, technologies et medecines</json:string><json:string>2 - sciences biologiques et medicales</json:string><json:string>3 - sciences medicales</json:string></inist></categories><publicationDate>2005</publicationDate><copyrightDate>2005</copyrightDate><doi><json:string>10.1002/pds.1030</json:string></doi><id>2373BA77F1E26EB00479968C030A9652218EB467</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-FRP40FW4-3/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-FRP40FW4-3/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/WNG-FRP40FW4-3/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main">Current awareness: Pharmacoepidemiology and drug safety</title><title level="a" type="short" xml:lang="en">Current Awareness</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>John Wiley & Sons, Ltd.</publisher><pubPlace>Chichester, UK</pubPlace><availability><licence>Copyright © 2005 John Wiley & Sons, Ltd.</licence></availability><date type="published" when="2005-08"></date></publicationStmt><notesStmt><note type="content-type" subtype="other" source="bibliography" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-7474895G-0">other</note><note type="publication-type" subtype="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note></notesStmt><sourceDesc><biblStruct type="other"><analytic><title level="a" type="main">Current awareness: Pharmacoepidemiology and drug safety</title><title level="a" type="short" xml:lang="en">Current Awareness</title><idno type="istex">2373BA77F1E26EB00479968C030A9652218EB467</idno><idno type="ark">ark:/67375/WNG-FRP40FW4-3</idno><idno type="DOI">10.1002/pds.1030</idno><idno type="unit">PDS1030</idno><idno type="toTypesetVersion">file:PDS.PDS1030.pdf</idno></analytic><monogr><title level="j" type="main">Pharmacoepidemiology and Drug Safety</title><title level="j" type="alt">PHARMACOEPIDEMIOLOGY AND DRUG SAFETY</title><idno type="pISSN">1053-8569</idno><idno type="eISSN">1099-1557</idno><idno type="book-DOI">10.1002/(ISSN)1099-1557</idno><idno type="book-part-DOI">10.1002/pds.v14:8</idno><idno type="product">PDS</idno><imprint><biblScope unit="vol">14</biblScope><biblScope unit="issue">8</biblScope><biblScope unit="page" from="i">i</biblScope><biblScope unit="page" to="xii">xii</biblScope><biblScope unit="page-count">12</biblScope><publisher>John Wiley & Sons, Ltd.</publisher><pubPlace>Chichester, UK</pubPlace><date type="published" when="2005-08"></date></imprint></monogr></biblStruct></sourceDesc></fileDesc><encodingDesc><schemaRef type="ODD" url="https://xml-schema.delivery.istex.fr/tei-istex.odd"></schemaRef><appInfo><application ident="pub2tei" version="1.0.10" when="2019-12-20"><label>pub2TEI-ISTEX</label><desc>A set of style sheets for converting XML documents encoded in various scientific publisher formats into a common TEI format.
<ref target="http://www.tei-c.org/">We use TEI</ref></desc></application></appInfo></encodingDesc><profileDesc><abstract xml:lang="en" style="main"><head>Abstract</head><p>In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 20 sections: 1 Books, Reviews & Symposia; 2 General; 3 Anti‐infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non‐steroidal Anti‐inflammatory Agents; 7 CNS Agents; 8 Anti‐neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator‐Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti‐inflammatory Agents ‐ Steroidal; 19 Teratogens/fetal exposure; 20 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted.</p></abstract><textClass><keywords rend="articleCategory"><term>Current Awareness</term></keywords><keywords rend="tocHeading1"><term>Current Awareness</term></keywords></textClass><langUsage><language ident="en"></language></langUsage></profileDesc><revisionDesc><change when="2019-12-20" who="#istex" xml:id="pub2tei">formatting</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-FRP40FW4-3/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>John Wiley & Sons, Ltd.</publisherName><publisherLoc>Chichester, UK</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1099-1557</doi><issn type="print">1053-8569</issn><issn type="electronic">1099-1557</issn><idGroup><id type="product" value="PDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="PHARMACOEPIDEMIOLOGY AND DRUG SAFETY">Pharmacoepidemiology and Drug Safety</title><title type="short">Pharmacoepidem. Drug Safe.</title></titleGroup></publicationMeta><publicationMeta level="part" position="80"><doi origin="wiley" registered="yes">10.1002/pds.v14:8</doi><numberingGroup><numbering type="journalVolume" number="14">14</numbering><numbering type="journalIssue">8</numbering></numberingGroup><coverDate startDate="2005-08">August 2005</coverDate></publicationMeta><publicationMeta level="unit" type="bibliography" position="999" status="forIssue"><doi origin="wiley" registered="yes">10.1002/pds.1030</doi><idGroup><id type="unit" value="PDS1030"></id></idGroup><countGroup><count type="pageTotal" number="12"></count></countGroup><titleGroup><title type="articleCategory">Current Awareness</title><title type="tocHeading1">Current Awareness</title></titleGroup><copyright ownership="publisher">Copyright © 2005 John Wiley & Sons, Ltd.</copyright><eventGroup><event type="firstOnline" date="2005-07-25"></event><event type="publishedOnlineFinalForm" date="2005-07-25"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.12 mode:FullText source:HeaderRef result:HeaderRef" date="2010-07-09"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-06"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-11-03"></event></eventGroup><numberingGroup><numbering type="pageFirst">i</numbering><numbering type="pageLast">xii</numbering></numberingGroup><linkGroup><link type="toTypesetVersion" href="file:PDS.PDS1030.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="0"></count><count type="referenceTotal" number="332"></count></countGroup><titleGroup><title type="main" xml:lang="en">Current awareness: Pharmacoepidemiology and drug safety</title><title type="short" xml:lang="en">Current Awareness</title></titleGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 20 sections: 1 Books, Reviews & Symposia; 2 General; 3 Anti‐infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non‐steroidal Anti‐inflammatory Agents; 7 CNS Agents; 8 Anti‐neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator‐Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti‐inflammatory Agents ‐ Steroidal; 19 Teratogens/fetal exposure; 20 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Current awareness: Pharmacoepidemiology and drug safety</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Current Awareness</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Current awareness: Pharmacoepidemiology and drug safety</title></titleInfo><typeOfResource>text</typeOfResource><genre type="other" displayLabel="bibliography" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-7474895G-0">other</genre><originInfo><publisher>John Wiley & Sons, Ltd.</publisher><place><placeTerm type="text">Chichester, UK</placeTerm></place><dateIssued encoding="w3cdtf">2005-08</dateIssued><copyrightDate encoding="w3cdtf">2005</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><extent unit="figures">0</extent><extent unit="tables">0</extent><extent unit="references">332</extent></physicalDescription><abstract lang="en">In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 20 sections: 1 Books, Reviews & Symposia; 2 General; 3 Anti‐infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non‐steroidal Anti‐inflammatory Agents; 7 CNS Agents; 8 Anti‐neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator‐Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti‐inflammatory Agents ‐ Steroidal; 19 Teratogens/fetal exposure; 20 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted.</abstract><relatedItem type="host"><titleInfo><title>Pharmacoepidemiology and Drug Safety</title></titleInfo><titleInfo type="abbreviated"><title>Pharmacoepidem. Drug Safe.</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><subject><genre>article-category</genre><topic>Current Awareness</topic><topic>Current Awareness</topic></subject><identifier type="ISSN">1053-8569</identifier><identifier type="eISSN">1099-1557</identifier><identifier type="DOI">10.1002/(ISSN)1099-1557</identifier><identifier type="PublisherID">PDS</identifier><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>14</number></detail><detail type="issue"><caption>no.</caption><number>8</number></detail><extent unit="pages"><start>i</start><end>xii</end><total>12</total></extent></part></relatedItem><relatedItem type="references" displayLabel="cit1"><titleInfo><title>1. Books, Reviews & Symposia</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit2"><titleInfo><title>Special issue on emesis in cancer therapy and the use of antiemetics</title></titleInfo><genre>journal-article</genre><note type="citation/reference">Special issue on emesis in cancer therapy and the use of antiemetics. Support Care Cancer (2005); 13:</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>13</number></detail></part><relatedItem type="host"><titleInfo><title>Support Care Cancer</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>13</number></detail></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit3"><titleInfo><title>Special issue: Drug‐induced thrombocytopenia: Focus on heparin‐induced thrombocytopenia</title></titleInfo><genre>journal-article</genre><note type="citation/reference">Special issue: Drug‐induced thrombocytopenia: Focus on heparin‐induced thrombocytopenia. Chest (2005); 127:</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>127</number></detail></part><relatedItem type="host"><titleInfo><title>Chest</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>127</number></detail></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit4"><titleInfo><title>Special issue: Hematologic side effects of hepatitis C therapy and their management</title></titleInfo><genre>journal-article</genre><note type="citation/reference">Special issue: Hematologic side effects of hepatitis C therapy and their management. J Clin Gastroenterol (2005); 39:</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>39</number></detail></part><relatedItem type="host"><titleInfo><title>J Clin Gastroenterol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>39</number></detail></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit5"><titleInfo><title>Special issue: Improving the use and safety of the medications in women through sex/gender and race/ethnicity analysis</title></titleInfo><genre>journal-article</genre><note type="citation/reference">Special issue: Improving the use and safety of the medications in women through sex/gender and race/ethnicity analysis. J Womens Health (2005); 14:</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>14</number></detail></part><relatedItem type="host"><titleInfo><title>J Womens Health</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>14</number></detail></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit6"><titleInfo><title>Weight‐based dosing: Which impact on efficacy and safety of therapy?</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Almasio PL. Weight‐based dosing: Which impact on efficacy and safety of therapy?. Dig Liver Dis (2004); 36: S349.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>36</number></detail><extent unit="pages"><start>S349</start></extent></part><relatedItem type="host"><titleInfo><title>Dig Liver Dis</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>36</number></detail><extent unit="pages"><start>S349</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit7"><titleInfo><title>Interactions between antiretrovirals and antineoplastic drug therapy (Review)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Antoniou T, Tseng AL. Interactions between antiretrovirals and antineoplastic drug therapy (Review). Clin Pharmacokinet (2005); 44: 111.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>44</number></detail><extent unit="pages"><start>111</start></extent></part><relatedItem type="host"><titleInfo><title>Clin Pharmacokinet</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>44</number></detail><extent unit="pages"><start>111</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit8"><titleInfo><title>Benefit‐risk‐assessment of the levonorgestrel intrauterine system in contraception (Review)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Backman T. Benefit‐risk‐assessment of the levonorgestrel intrauterine system in contraception (Review). Drug Saf (2004); 27: 1185.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>1185</start></extent></part><relatedItem type="host"><titleInfo><title>Drug Saf</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>1185</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit9"><titleInfo><title>Current approaches to prevent NSAID‐induced gastropathy ‐ COX selectivity and beyond (Review)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Becker JC, Domschke W, Pohle T. Current approaches to prevent NSAID‐induced gastropathy ‐ COX selectivity and beyond (Review). Br J Clin Pharmacol (2004); 58: 587.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>58</number></detail><extent unit="pages"><start>587</start></extent></part><relatedItem type="host"><titleInfo><title>Br J Clin Pharmacol</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>58</number></detail><extent unit="pages"><start>587</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit10"><titleInfo><title>Pruritus precipitated by hydroxyethyl starch: A review</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Bork K. Pruritus precipitated by hydroxyethyl starch: A review. Br J Dermatol (2005); 152: 3.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>152</number></detail><extent unit="pages"><start>3</start></extent></part><relatedItem type="host"><titleInfo><title>Br J Dermatol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>152</number></detail><extent unit="pages"><start>3</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit11"><titleInfo><title>Ovulation induction and cancer risk</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Brinton LA, Moghissi KS, Scoccia B, Westhoff CL, Lamb EJ. Ovulation induction and cancer risk. Fertil Steril (2005); 83: 261.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>83</number></detail><extent unit="pages"><start>261</start></extent></part><relatedItem type="host"><titleInfo><title>Fertil Steril</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>83</number></detail><extent unit="pages"><start>261</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit12"><titleInfo><title>Hyperlactataemia and lactic acidosis in HIV‐infected patients receiving antiretroviral therapy (Review)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Calza L, Manfredi R, Chiodo F. Hyperlactataemia and lactic acidosis in HIV‐infected patients receiving antiretroviral therapy (Review). Clin Nutr (2005); 24: 5.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>24</number></detail><extent unit="pages"><start>5</start></extent></part><relatedItem type="host"><titleInfo><title>Clin Nutr</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>24</number></detail><extent unit="pages"><start>5</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit13"><titleInfo><title>Adverse effects of tocolytic therapy</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Caritis S. Adverse effects of tocolytic therapy. BJOG (2005); 112: 74.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>112</number></detail><extent unit="pages"><start>74</start></extent></part><relatedItem type="host"><titleInfo><title>BJOG</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>112</number></detail><extent unit="pages"><start>74</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit14"><titleInfo><title>Safety issues regarding colonic cleansing for diagnostic and surgical procedures (Review)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Clark LE, DiPalma JA. Safety issues regarding colonic cleansing for diagnostic and surgical procedures (Review). Drug Saf (2004); 27: 1235.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>1235</start></extent></part><relatedItem type="host"><titleInfo><title>Drug Saf</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>1235</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit15"><titleInfo><title>Tolerability profile of metformin/glibenclamide combination tablets (Glucovance(R)) A new treatment for the management of type 2 diabetes mellitus (Review)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Davidson JA, Scheen AJ, Howlett HCS. Tolerability profile of metformin/glibenclamide combination tablets (Glucovance(R)) A new treatment for the management of type 2 diabetes mellitus (Review). Drug Saf (2004); 27: 1205.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>1205</start></extent></part><relatedItem type="host"><titleInfo><title>Drug Saf</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>1205</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit16"><titleInfo><title>Tolerability of treatments for postherpetic neuralgia (Review)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Douglas MW, Johnson RW, Cunningham AL. Tolerability of treatments for postherpetic neuralgia (Review). Drug Saf (2004); 27: 1217.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>1217</start></extent></part><relatedItem type="host"><titleInfo><title>Drug Saf</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>1217</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit17"><titleInfo><title>Deaths in children with Prader‐Willi syndrome ‐ A contribution to the debate about the safety of growth hormone treatment in children with PWS (Review)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Eiholzer U. Deaths in children with Prader‐Willi syndrome ‐ A contribution to the debate about the safety of growth hormone treatment in children with PWS (Review). Horm Res (2005); 63: 33.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>63</number></detail><extent unit="pages"><start>33</start></extent></part><relatedItem type="host"><titleInfo><title>Horm Res</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>63</number></detail><extent unit="pages"><start>33</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit18"><titleInfo><title>Cardiac safety of liposomal anthracyclines</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ewer MS, Martin FJ, Henderson IC, Shapiro CL, Benjamin RS, Gabizon AA. Cardiac safety of liposomal anthracyclines. Semin Oncol (2004); 31: 161.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>31</number></detail><extent unit="pages"><start>161</start></extent></part><relatedItem type="host"><titleInfo><title>Semin Oncol</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>31</number></detail><extent unit="pages"><start>161</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit19"><titleInfo><title>Association between suicide attempts and selective serotonin reuptake inhibitors: Systematic review of randomised controlled trials</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Fergusson D, Doucette S, Cranley K, Glass KC, Shapiro S, Healy D, Hebert P, Hutton B. Association between suicide attempts and selective serotonin reuptake inhibitors: Systematic review of randomised controlled trials. Br Med J (2005); 330: 396.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>330</number></detail><extent unit="pages"><start>396</start></extent></part><relatedItem type="host"><titleInfo><title>Br Med J</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>330</number></detail><extent unit="pages"><start>396</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit20"><titleInfo><title>Low molecular weight heparin in pregnancy: Current issues (Review)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Greer I, Hunt BJ. Low molecular weight heparin in pregnancy: Current issues (Review). Br J Haematol (2005); 128: 593.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>128</number></detail><extent unit="pages"><start>593</start></extent></part><relatedItem type="host"><titleInfo><title>Br J Haematol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>128</number></detail><extent unit="pages"><start>593</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit21"><titleInfo><title>Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: Meta‐analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Gunnell D, Saperia G, Ashby D. Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: Meta‐analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review. Br Med J (2005); 330: 385.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>330</number></detail><extent unit="pages"><start>385</start></extent></part><relatedItem type="host"><titleInfo><title>Br Med J</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>330</number></detail><extent unit="pages"><start>385</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit22"><titleInfo><title>Heparin‐induced thrombocytopenia in the cardiovascular patient: Diagnostic and treatment guidelines (Review)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Gurbuz AT, Elliott WG, Zia AA. Heparin‐induced thrombocytopenia in the cardiovascular patient: Diagnostic and treatment guidelines (Review). Eur J Cardiothorac Surg (2005); 27: 138.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>138</start></extent></part><relatedItem type="host"><titleInfo><title>Eur J Cardiothorac Surg</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>138</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit23"><titleInfo><title>Herb‐drug interactions: An overview of the clinical evidence (Review)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Izzo AA. Herb‐drug interactions: An overview of the clinical evidence (Review). Fundam Clin Pharmacol (2005); 19: 1.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>19</number></detail><extent unit="pages"><start>1</start></extent></part><relatedItem type="host"><titleInfo><title>Fundam Clin Pharmacol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>19</number></detail><extent unit="pages"><start>1</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit24"><titleInfo><title>Cardiovascular pharmacotherapy and herbal medicines: The risk of drug interaction (Review)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Izzo AA, Di Carlo G, Borrelli F, Ernst E. Cardiovascular pharmacotherapy and herbal medicines: The risk of drug interaction (Review). Int J Cardiol (2005); 98: 1.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>98</number></detail><extent unit="pages"><start>1</start></extent></part><relatedItem type="host"><titleInfo><title>Int J Cardiol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>98</number></detail><extent unit="pages"><start>1</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit25"><titleInfo><title>Torsade de pointes induced by psychotropic drugs and the prevalence of its risk factors (Review)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Justo D, Prokhorov V, Heller K, Zeltser D. Torsade de pointes induced by psychotropic drugs and the prevalence of its risk factors (Review). Acta Psychiatr Scand (2005); 111: 171.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>111</number></detail><extent unit="pages"><start>171</start></extent></part><relatedItem type="host"><titleInfo><title>Acta Psychiatr Scand</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>111</number></detail><extent unit="pages"><start>171</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit26"><titleInfo><title>Minocycline‐associated intra‐oral soft‐tissue pigmentation: Clinicopathologic correlations and review</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">LaPorta VN, Nikitakis NG, Sindler AJ, Reynolds MA. Minocycline‐associated intra‐oral soft‐tissue pigmentation: Clinicopathologic correlations and review. J Clin Periodontol (2005); 32:</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>32</number></detail></part><relatedItem type="host"><titleInfo><title>J Clin Periodontol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>32</number></detail></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit27"><titleInfo><title>Doxazosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction: A systematic review of efficacy and adverse effects</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">MacDonald R, Wilt TJ, Howe RW. Doxazosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction: A systematic review of efficacy and adverse effects. BJU Int (2004); 94: 1263.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>94</number></detail><extent unit="pages"><start>1263</start></extent></part><relatedItem type="host"><titleInfo><title>BJU Int</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>94</number></detail><extent unit="pages"><start>1263</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit28"><titleInfo><title>Effects of inhaled corticosteroids on bone (Review)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Mortimer KJ, Harrison TW, Tattersfield AE. Effects of inhaled corticosteroids on bone (Review). Ann Allergy Asthma Immunol (2005); 94: 15.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>94</number></detail><extent unit="pages"><start>15</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Allergy Asthma Immunol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>94</number></detail><extent unit="pages"><start>15</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit29"><titleInfo><title>Hepatotoxicity of antiretrovirals ‐ Incidence, mechanisms and management (Review)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Nunez M, Soriano V. Hepatotoxicity of antiretrovirals ‐ Incidence, mechanisms and management (Review). Drug Saf (2005); 28: 53.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>53</start></extent></part><relatedItem type="host"><titleInfo><title>Drug Saf</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>53</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit30"><titleInfo><title>Pharmacokinetics, pharmacodynamics and drug interaction potential of enfuvirtide (Review)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Patel IH, Zhang XP, Nieforth K, Salgo M, Buss N. Pharmacokinetics, pharmacodynamics and drug interaction potential of enfuvirtide (Review). Clin Pharmacokinet (2005); 44: 175.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>44</number></detail><extent unit="pages"><start>175</start></extent></part><relatedItem type="host"><titleInfo><title>Clin Pharmacokinet</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>44</number></detail><extent unit="pages"><start>175</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit31"><titleInfo><title>Herbal remedies and anticoagulant therapy (Review)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Samuels N. Herbal remedies and anticoagulant therapy (Review). Thromb Haemost (2005); 93: 3.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>93</number></detail><extent unit="pages"><start>3</start></extent></part><relatedItem type="host"><titleInfo><title>Thromb Haemost</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>93</number></detail><extent unit="pages"><start>3</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit32"><titleInfo><title>A comparison of the adverse reactions associated with isosulfan blue versus methylene blue dye in for breast sentinel lymph node biopsy cancer (Review)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Thevarajah S, Huston TL, Simmons RM. A comparison of the adverse reactions associated with isosulfan blue versus methylene blue dye in for breast sentinel lymph node biopsy cancer (Review). Am J Surg (2005); 189: 236.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>189</number></detail><extent unit="pages"><start>236</start></extent></part><relatedItem type="host"><titleInfo><title>Am J Surg</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>189</number></detail><extent unit="pages"><start>236</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit33"><titleInfo><title>Pharmacoepidemiology of anabolic androgenic steroids: A review</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Thiblin I, Petersson A. Pharmacoepidemiology of anabolic androgenic steroids: A review. Fundam Clin Pharmacol (2005); 19: 27.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>19</number></detail><extent unit="pages"><start>27</start></extent></part><relatedItem type="host"><titleInfo><title>Fundam Clin Pharmacol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>19</number></detail><extent unit="pages"><start>27</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit34"><titleInfo><title>Atypical antipsychotics ‐ From potassium channels to torsade de pointes and sudden death (Review)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Titier K, Girodet PO, Verdoux H, Molimard M, Begaud B, Haverkamp W, Lader M, Moore N. Atypical antipsychotics ‐ From potassium channels to torsade de pointes and sudden death (Review). Drug Saf (2005); 28: 35.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>35</start></extent></part><relatedItem type="host"><titleInfo><title>Drug Saf</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>35</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit35"><titleInfo><title>Drug‐induced immune thrombocytopenia (Review)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Van den Bemt PMLA, Meyboom RHB, Egberts ACG. Drug‐induced immune thrombocytopenia (Review). Drug Saf (2004); 27: 1243.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>1243</start></extent></part><relatedItem type="host"><titleInfo><title>Drug Saf</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>1243</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit36"><titleInfo><title>Cyclophosphamide‐induced gonadal toxicity: A treatment dilemma in patients with lupus nephritis? (Review)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Wetzels JFM. Cyclophosphamide‐induced gonadal toxicity: A treatment dilemma in patients with lupus nephritis? (Review). Neth J Med (2004); 62: 347.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>62</number></detail><extent unit="pages"><start>347</start></extent></part><relatedItem type="host"><titleInfo><title>Neth J Med</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>62</number></detail><extent unit="pages"><start>347</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit37"><titleInfo><title>2. General</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit38"><titleInfo><title>Appraisal of the MedDRA conceptual structure for describing and grouping adverse drug reactions</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Bousquet C, Lagier G, Louet ALL, Le Beller C, Venot A, Jaulent MC. Appraisal of the MedDRA conceptual structure for describing and grouping adverse drug reactions. Drug Saf (2005); 28: 19.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>19</start></extent></part><relatedItem type="host"><titleInfo><title>Drug Saf</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>19</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit39"><titleInfo><title>The art and science of risk management ‐ A US research‐based industry perspective</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Bush JK, Dai WS, Dieck GS, Hostelley LS, Hassall T. The art and science of risk management ‐ A US research‐based industry perspective. Drug Saf (2005); 28: 1.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>1</start></extent></part><relatedItem type="host"><titleInfo><title>Drug Saf</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>1</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit40"><titleInfo><title>Sentinel systems are needed for long term adverse drug reactions (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Callreus T. Sentinel systems are needed for long term adverse drug reactions (Letter). Br Med J (2005); 330: 255.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>330</number></detail><extent unit="pages"><start>255</start></extent></part><relatedItem type="host"><titleInfo><title>Br Med J</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>330</number></detail><extent unit="pages"><start>255</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit41"><titleInfo><title>Incidence and possible causes of prescribing potentially hazardous/contraindicated drug combinations in general practice</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Chen YF, Avery AJ, Neil KE, Johnson C, Dewey ME, Stockley IH. Incidence and possible causes of prescribing potentially hazardous/contraindicated drug combinations in general practice. Drug Saf (2005); 28: 67.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>67</start></extent></part><relatedItem type="host"><titleInfo><title>Drug Saf</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>67</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit42"><titleInfo><title>Linking pharmacovigilance with pharmacogenetics</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Clark DWJ, Donnelly E, Coulter DM, Roberts RL, Kennedy MA. Linking pharmacovigilance with pharmacogenetics. Drug Saf (2004); 27: 1171.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>1171</start></extent></part><relatedItem type="host"><titleInfo><title>Drug Saf</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>1171</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit43"><titleInfo><title>Pharmacists' discussions of medication side effects: A descriptive study</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Dyck A, Deschamps M, Taylor J. Pharmacists' discussions of medication side effects: A descriptive study. Patient Educ Couns (2005); 56: 21.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>56</number></detail><extent unit="pages"><start>21</start></extent></part><relatedItem type="host"><titleInfo><title>Patient Educ Couns</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>56</number></detail><extent unit="pages"><start>21</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit44"><titleInfo><title>An algorithmic computerised order entry approach to assist in the prescribing of new therapeutic agents ‐ Case study of activated protein C at an academic medical centre</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Fischer MA, Lilly CM, Churchill WW, Baden LR, Avorn J. An algorithmic computerised order entry approach to assist in the prescribing of new therapeutic agents ‐ Case study of activated protein C at an academic medical centre. Drug Saf (2004); 27: 1253.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>1253</start></extent></part><relatedItem type="host"><titleInfo><title>Drug Saf</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>1253</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit45"><titleInfo><title>Pattern of drug prescription for children under the age of four years in a population in Greenland</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Hahn GH, Koch A, Melbye M, Molbak K. Pattern of drug prescription for children under the age of four years in a population in Greenland. Acta Paediatr (2005); 94: 99.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>94</number></detail><extent unit="pages"><start>99</start></extent></part><relatedItem type="host"><titleInfo><title>Acta Paediatr</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>94</number></detail><extent unit="pages"><start>99</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit46"><titleInfo><title>Adverse drug events caused by medication errors in medical inpatients</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Hardmeier B, Braunschweig S, Cavallaro M, Roos M, Pauli‐Magnus C, Giger M, Meier PJ, Fattinger K. Adverse drug events caused by medication errors in medical inpatients. Swiss Med Wkly (2004); 134: 664.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>134</number></detail><extent unit="pages"><start>664</start></extent></part><relatedItem type="host"><titleInfo><title>Swiss Med Wkly</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>134</number></detail><extent unit="pages"><start>664</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit47"><titleInfo><title>A pharmacoepidemiological study of prescription pattern in outpatient clinics in Southwestern Saudi Arabia</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Irshaid YM, Al‐Homrany MA, Hamdi AA, Adjepon‐Yamoah KK, Mahfouz AA. A pharmacoepidemiological study of prescription pattern in outpatient clinics in Southwestern Saudi Arabia. Saudi Med J (2004); 25: 1864.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>1864</start></extent></part><relatedItem type="host"><titleInfo><title>Saudi Med J</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>1864</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit48"><titleInfo><title>A pharmacoepidemiological approach to investigating inappropriate physician prescribing in a managed care setting in Israel</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kahan NR, Blackman S, Kutz C, Waitman DA. A pharmacoepidemiological approach to investigating inappropriate physician prescribing in a managed care setting in Israel. Am J Managed Care (2005); 11: 89.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>11</number></detail><extent unit="pages"><start>89</start></extent></part><relatedItem type="host"><titleInfo><title>Am J Managed Care</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>11</number></detail><extent unit="pages"><start>89</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit49"><titleInfo><title>Drug combinations and impaired renal function ‐ The ‘triple whammy’</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Loboz KK, Shenfield GM. Drug combinations and impaired renal function ‐ The ‘triple whammy’. Br J Clin Pharmacol (2005); 59: 239.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>59</number></detail><extent unit="pages"><start>239</start></extent></part><relatedItem type="host"><titleInfo><title>Br J Clin Pharmacol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>59</number></detail><extent unit="pages"><start>239</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit50"><titleInfo><title>Effect of information on reported adverse events in a placebo‐controlled trial</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ossege M, Sycha T, Aigner M, Schmetterer L, Eichler H, Muller M, Konig F, Bauer P. Effect of information on reported adverse events in a placebo‐controlled trial. Drug Saf (2005); 28: 81.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>81</start></extent></part><relatedItem type="host"><titleInfo><title>Drug Saf</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>81</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit51"><titleInfo><title>Drug‐induced myocardial infarction in young patients: Report of two cases (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Papp E, Czopf L, Habon T, Halmosi R, Horvath B, Marton Z, Tahin T, Komocsi A, Horvath I, Melegh B, Toth K. Drug‐induced myocardial infarction in young patients: Report of two cases (Letter). Int J Cardiol (2005); 98: 169.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>98</number></detail><extent unit="pages"><start>169</start></extent></part><relatedItem type="host"><titleInfo><title>Int J Cardiol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>98</number></detail><extent unit="pages"><start>169</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit52"><titleInfo><title>Adverse outcomes associated with inappropriate drug use in nursing homes</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Perri M, Menon AM, Deshpande AD, Shinde SB, Jiang R, Cooper JW, Cook CL, Griffin SC, Lorys RA. Adverse outcomes associated with inappropriate drug use in nursing homes. Ann Pharmacother (2005); 39: 405.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>405</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Pharmacother</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>405</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit53"><titleInfo><title>An underrecognized challenge in evaluating postmarketing drug safety (Editorial)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Roden DM. An underrecognized challenge in evaluating postmarketing drug safety (Editorial). Circulation (2005); 111: 246.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>111</number></detail><extent unit="pages"><start>246</start></extent></part><relatedItem type="host"><titleInfo><title>Circulation</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>111</number></detail><extent unit="pages"><start>246</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit54"><titleInfo><title>Drug‐drug interactions: The silent epidemic</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Sandson N. Drug‐drug interactions: The silent epidemic. Psychiatr Serv (2005); 56: 22.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>56</number></detail><extent unit="pages"><start>22</start></extent></part><relatedItem type="host"><titleInfo><title>Psychiatr Serv</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>56</number></detail><extent unit="pages"><start>22</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit55"><titleInfo><title>Adverse drug reaction and medication error reporting by pharmacy students</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Sears EL, Generali JA. Adverse drug reaction and medication error reporting by pharmacy students. Ann Pharmacother (2005); 39: 452.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>452</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Pharmacother</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>452</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit56"><titleInfo><title>Post‐marketing drug safety in the era of genomic medicine (Editorial)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Zavras AI. Post‐marketing drug safety in the era of genomic medicine (Editorial). J Dent Res (2004); 84: 105.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>84</number></detail><extent unit="pages"><start>105</start></extent></part><relatedItem type="host"><titleInfo><title>J Dent Res</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>84</number></detail><extent unit="pages"><start>105</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit57"><titleInfo><title>3. Anti‐infective Agents</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit58"><titleInfo><title>Rhabdomyolysis due to lamivudine administration in a liver transplant recipient (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Adani GL, Baccarani U, Risaliti A, Bresadola F, Della Rocca G, Viale P. Rhabdomyolysis due to lamivudine administration in a liver transplant recipient (Letter). Am J Transplant (2005); 5: 634.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>5</number></detail><extent unit="pages"><start>634</start></extent></part><relatedItem type="host"><titleInfo><title>Am J Transplant</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>5</number></detail><extent unit="pages"><start>634</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit59"><titleInfo><title>Parental vaccine safety concerns ‐ Results from the National Immunization Survey, 2001‐2002</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Allred NJ, Shaw KM, Santibanez TA, Rickert DL, Santoli JM. Parental vaccine safety concerns ‐ Results from the National Immunization Survey, 2001‐2002. Am J Prev Med (2005); 28: 221.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>221</start></extent></part><relatedItem type="host"><titleInfo><title>Am J Prev Med</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>221</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit60"><titleInfo><title>Blockade of HERG channels by HIV protease inhibitors</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Anson BD, Weaver JGR, Ackerman MJ, Akinsete O, Henry K, January CT, Badley AD. Blockade of HERG channels by HIV protease inhibitors. Lancet (2005); 365: 682.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>365</number></detail><extent unit="pages"><start>682</start></extent></part><relatedItem type="host"><titleInfo><title>Lancet</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>365</number></detail><extent unit="pages"><start>682</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit61"><titleInfo><title>Rupture of multiple tendons after levofloxacin therapy (Case Report)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Braun D, Petitpain N, Cosserat F, Loeuille D, Bitar S, Gillet P, Trechot P. Rupture of multiple tendons after levofloxacin therapy (Case Report). Joint Bone Spine (2004); 71: 586.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>71</number></detail><extent unit="pages"><start>586</start></extent></part><relatedItem type="host"><titleInfo><title>Joint Bone Spine</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>71</number></detail><extent unit="pages"><start>586</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit62"><titleInfo><title>Pharmacokinetics and hepatotoxicity of lopinavir/ritonavir in non‐cirrhotic HIV and hepatitis C virus (HCV) co‐infected patients</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Canta F, Marrone R, Bonora S, D'Avolio A, Sciandra M, Sinicco A, De Rosa FG, Di Perri G. Pharmacokinetics and hepatotoxicity of lopinavir/ritonavir in non‐cirrhotic HIV and hepatitis C virus (HCV) co‐infected patients. J Antimicrob Chemother (2005); 55: 280.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>55</number></detail><extent unit="pages"><start>280</start></extent></part><relatedItem type="host"><titleInfo><title>J Antimicrob Chemother</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>55</number></detail><extent unit="pages"><start>280</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit63"><titleInfo><title>Irreversible sensorineural hearing loss due to clarithromycin</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Coulston J, Balaratnam N. Irreversible sensorineural hearing loss due to clarithromycin. Postgrad Med J (2005); 81: 58.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>81</number></detail><extent unit="pages"><start>58</start></extent></part><relatedItem type="host"><titleInfo><title>Postgrad Med J</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>81</number></detail><extent unit="pages"><start>58</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit64"><titleInfo><title>Probable vancomycin‐associated toxic epidermal necrolysis (Case Report)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Craycraft ME, Arunakul VL, Humeniuk JM. Probable vancomycin‐associated toxic epidermal necrolysis (Case Report). Pharmacotherapy (2005); 25: 308.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>308</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacotherapy</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>308</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit65"><titleInfo><title>A persistent ulceration after a fortuitous BCG revaccination (French)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Cuchet E, Templier I, Brion JP, Beani JC. A persistent ulceration after a fortuitous BCG revaccination (French). Ann Dermatol Venereol (2004); 131: 1077.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>131</number></detail><extent unit="pages"><start>1077</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Dermatol Venereol</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>131</number></detail><extent unit="pages"><start>1077</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit66"><titleInfo><title>Vestibular toxic effects induced by once‐daily aminoglycoside therapy</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Dhanireddy S, Liles C, Gates GA. Vestibular toxic effects induced by once‐daily aminoglycoside therapy. Arch Otolaryngol Head Neck Surg (2005); 131: 46.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>131</number></detail><extent unit="pages"><start>46</start></extent></part><relatedItem type="host"><titleInfo><title>Arch Otolaryngol Head Neck Surg</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>131</number></detail><extent unit="pages"><start>46</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit67"><titleInfo><title>Influence of ketoconazole on azimilide pharmacokinetics in healthy subjects</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">El Mouelhi M, Worley DJ, Kuzmak B, Destefano AJ, Thompson GA. Influence of ketoconazole on azimilide pharmacokinetics in healthy subjects. Br J Clin Pharmacol (2004); 58: 641.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>58</number></detail><extent unit="pages"><start>641</start></extent></part><relatedItem type="host"><titleInfo><title>Br J Clin Pharmacol</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>58</number></detail><extent unit="pages"><start>641</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit68"><titleInfo><title>Moxifloxacin‐warfarin interaction: A series of five case reports</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Elbe DHT, Chang SW. Moxifloxacin‐warfarin interaction: A series of five case reports. Ann Pharmacother (2005); 39: 361.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>361</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Pharmacother</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>361</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit69"><titleInfo><title>Minocycline has no effect on the fibrinolytic activity of alteplase (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Farooq MU, Zemke D, Majid A. Minocycline has no effect on the fibrinolytic activity of alteplase (Letter). Ann Pharmacother (2005); 39: 387.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>387</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Pharmacother</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>387</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit70"><titleInfo><title>Clarithromycin‐nifedipine interaction as possible cause of vasodilatory shock (Case Report)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Geronimo‐Pardo M, Cuartero‐del‐Pozo AB, Jimenez‐Vizuete JM, Cortinas‐Saez M, Peyro‐Garcia R. Clarithromycin‐nifedipine interaction as possible cause of vasodilatory shock (Case Report). Ann Pharmacother (2005); 39: 538.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>538</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Pharmacother</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>538</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit71"><titleInfo><title>Current opinion 2004: The relationship between multiple sclerosis and hepatitis B vaccination in adults (Editorial) (French)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Gout O, Lyon‐Caen O. Current opinion 2004: The relationship between multiple sclerosis and hepatitis B vaccination in adults (Editorial) (French). Rev Neurol (Paris) (2004); 160: 1147.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>160</number></detail><extent unit="pages"><start>1147</start></extent></part><relatedItem type="host"><titleInfo><title>Rev Neurol (Paris)</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>160</number></detail><extent unit="pages"><start>1147</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit72"><titleInfo><title>Impact of dyslipidemia associated with highly active antiretroviral therapy (HAART) on cardiovascular risk and life expectancy</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Grover SA, Coupal L, Gilmore N, Mukherjee J. Impact of dyslipidemia associated with highly active antiretroviral therapy (HAART) on cardiovascular risk and life expectancy. Am J Cardiol (2005); 95: 586.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>95</number></detail><extent unit="pages"><start>586</start></extent></part><relatedItem type="host"><titleInfo><title>Am J Cardiol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>95</number></detail><extent unit="pages"><start>586</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit73"><titleInfo><title>Severe febrile systemic reaction to pneumococcal vaccine (Case Report)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Hasan S, Yousef M, Shridharani S. Severe febrile systemic reaction to pneumococcal vaccine (Case Report). J Natl Med Assoc (2005); 97: 284.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>97</number></detail><extent unit="pages"><start>284</start></extent></part><relatedItem type="host"><titleInfo><title>J Natl Med Assoc</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>97</number></detail><extent unit="pages"><start>284</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit74"><titleInfo><title>A case report of rhabdomyolysis with pentamidine that prompted a retrospective evaluation of a pharmacovigilance tool under investigation (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Hauben M, Reich L. A case report of rhabdomyolysis with pentamidine that prompted a retrospective evaluation of a pharmacovigilance tool under investigation (Letter). Br J Clin Pharmacol (2004); 58: 675.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>58</number></detail><extent unit="pages"><start>675</start></extent></part><relatedItem type="host"><titleInfo><title>Br J Clin Pharmacol</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>58</number></detail><extent unit="pages"><start>675</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit75"><titleInfo><title>Interactions between clarithromycin and digoxin in patients with end‐stage renal disease</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Hirata S, Izumi S, Furukubo T, Ota M, Fujita M, Yamakawa T, Hasegawa I, Ohtani H, Sawada Y. Interactions between clarithromycin and digoxin in patients with end‐stage renal disease. Int J Clin Pharmacol Ther (2005); 43: 30.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>43</number></detail><extent unit="pages"><start>30</start></extent></part><relatedItem type="host"><titleInfo><title>Int J Clin Pharmacol Ther</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>43</number></detail><extent unit="pages"><start>30</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit76"><titleInfo><title>Sulfonamide cross‐reactivity: Fact or fiction?</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Johnson KK, Green DL, Rife JP, Limon L. Sulfonamide cross‐reactivity: Fact or fiction?. Ann Pharmacother (2005); 39: 290.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>290</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Pharmacother</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>290</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit77"><titleInfo><title>Acute febrile neutrophilic dermatosis (Sweet's syndrome) after influenza vaccination (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Jovanovic M, Poljacki M, Vujanovic L, Duran V. Acute febrile neutrophilic dermatosis (Sweet's syndrome) after influenza vaccination (Letter). J Am Acad Dermatol (2005); 52: 367.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>52</number></detail><extent unit="pages"><start>367</start></extent></part><relatedItem type="host"><titleInfo><title>J Am Acad Dermatol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>52</number></detail><extent unit="pages"><start>367</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit78"><titleInfo><title>Major depressive disorder with psychotic features induced by interferon‐α treatment for hepatitis C in a polydrug abuser</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kalyoncu OA, Tan D, Mirsal H, Pektas O, Beyazyurek M. Major depressive disorder with psychotic features induced by interferon‐α treatment for hepatitis C in a polydrug abuser. J Psychopharmacol (2005); 19: 102.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>19</number></detail><extent unit="pages"><start>102</start></extent></part><relatedItem type="host"><titleInfo><title>J Psychopharmacol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>19</number></detail><extent unit="pages"><start>102</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit79"><titleInfo><title>Furazolidone‐induced pulmonary hypersensitivity (Case Report)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kowalski TJ, Henry MJ, Zlabek JA. Furazolidone‐induced pulmonary hypersensitivity (Case Report). Ann Pharmacother (2005); 39: 377.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>377</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Pharmacother</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>377</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit80"><titleInfo><title>Neurocognitive changes in patients with hepatitis C receiving interferon alpha;‐2b and ribavirin</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kraus MR, Schafer A, Wissmann S, Reimer P, Scheurlen M. Neurocognitive changes in patients with hepatitis C receiving interferon alpha;‐2b and ribavirin. Clin Pharmacol Ther (2005); 77: 90.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>77</number></detail><extent unit="pages"><start>90</start></extent></part><relatedItem type="host"><titleInfo><title>Clin Pharmacol Ther</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>77</number></detail><extent unit="pages"><start>90</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit81"><titleInfo><title>Tenofovir‐induced acute renal failure in an HIV patient with normal renal function (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Krummell T, Parvez‐Braun L, Frantzen L, Lalanne H, Marcellin L, Hannedouche T, Moulin B. Tenofovir‐induced acute renal failure in an HIV patient with normal renal function (Letter). Nephrol Dial Transplant (2005); 20: 473.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><extent unit="pages"><start>473</start></extent></part><relatedItem type="host"><titleInfo><title>Nephrol Dial Transplant</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><extent unit="pages"><start>473</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit82"><titleInfo><title>Effect of efavirenz treatment on the pharmacokinetics of nelfinavir boosted by ritonavir in healthy volunteers</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">La Porte CJL, De Graaff‐Teulen MJA, Colbers EPH, Voncken DS, Ibanez SM, Koopmans PP, Hekster YA, Burger DM. Effect of efavirenz treatment on the pharmacokinetics of nelfinavir boosted by ritonavir in healthy volunteers. Br J Clin Pharmacol (2004); 58: 632.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>58</number></detail><extent unit="pages"><start>632</start></extent></part><relatedItem type="host"><titleInfo><title>Br J Clin Pharmacol</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>58</number></detail><extent unit="pages"><start>632</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit83"><titleInfo><title>A generalized reaction to thimerosal from an influenza vaccine (Case Reports)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Lee‐Wong M, Resnick D, Chong K. A generalized reaction to thimerosal from an influenza vaccine (Case Reports). Ann Allergy Asthma Immunol (2005); 94: 90.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>94</number></detail><extent unit="pages"><start>90</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Allergy Asthma Immunol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>94</number></detail><extent unit="pages"><start>90</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit84"><titleInfo><title>Refractory anaphylactic shock associated with ketoconazole treatment (Case Report)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Liu PY, Lee CH, Lin LJ, Chen JH. Refractory anaphylactic shock associated with ketoconazole treatment (Case Report). Ann Pharmacother (2005); 39: 547.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>547</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Pharmacother</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>547</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit85"><titleInfo><title>Efficacy and safety of abacavir plus lamivudine versus didanosine plus stavudine when combined with a protease inhibitor, a nonnucleoside reverse transcriptase inhibitor, or both in HIV‐1 positive antiretroviral‐naive persons</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">MacArthur RD, Chen L, Peng G, Novak RM, Van den Berg‐Wolf M, Kozal M, Besch L, Yurik T, Schmetter B, Henley C, Dehlinger M. Efficacy and safety of abacavir plus lamivudine versus didanosine plus stavudine when combined with a protease inhibitor, a nonnucleoside reverse transcriptase inhibitor, or both in HIV‐1 positive antiretroviral‐naive persons. HIV Clin Trials (2004); 5: 361.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>5</number></detail><extent unit="pages"><start>361</start></extent></part><relatedItem type="host"><titleInfo><title>HIV Clin Trials</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>5</number></detail><extent unit="pages"><start>361</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit86"><titleInfo><title>Safety of the combination of chloroquine and methylene blue in healthy adult men with G6PD deficiency Faso</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Mandi G, Witte S, Meissner P, Coulibaly B, Mansmann U, Rengelshausen J, Schiek W, Jahn A, Sanon M, Wust K, Walter‐Sack I, Mikus G, Burhenne J, Riedel KD, Schirmer H, Kouyate B, Muller O. Safety of the combination of chloroquine and methylene blue in healthy adult men with G6PD deficiency Faso. Trop Med Int Health (2005); 10: 32.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>10</number></detail><extent unit="pages"><start>32</start></extent></part><relatedItem type="host"><titleInfo><title>Trop Med Int Health</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>10</number></detail><extent unit="pages"><start>32</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit87"><titleInfo><title>Multicenter study on the immunogenicity and safety of two recombinant vaccines against hepatitis B</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Martins RM, Bensabath G, Arraes LC, Oliveira MDA, Miguel JC, Barbosa GG, Camacho LAB. Multicenter study on the immunogenicity and safety of two recombinant vaccines against hepatitis B. Mem Inst Oswaldo Cruz (2004); 99: 865.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>99</number></detail><extent unit="pages"><start>865</start></extent></part><relatedItem type="host"><titleInfo><title>Mem Inst Oswaldo Cruz</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>99</number></detail><extent unit="pages"><start>865</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit88"><titleInfo><title>Adverse events after inactivated influenza vaccination among children less than 2 years of age: Analysis of reports from the Vaccine Adverse Event Reporting System, 1990‐2003</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">McMahon AW, Iskander J, Haber P, Chang SJ, Woo EJ, Braun MM, Ball R. Adverse events after inactivated influenza vaccination among children less than 2 years of age: Analysis of reports from the Vaccine Adverse Event Reporting System, 1990‐2003. Pediatrics (2005); 115: 453.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>115</number></detail><extent unit="pages"><start>453</start></extent></part><relatedItem type="host"><titleInfo><title>Pediatrics</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>115</number></detail><extent unit="pages"><start>453</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit89"><titleInfo><title>Safety and immunogenicity of gelatin‐free varicella vaccine in epidemiological and serological studies in Japan</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ozaki T, Nishimura N, Muto T, Sugata K, Kawabe S, Goto K, Koyama K, Fujita H, Takahashi Y, Akiyama M. Safety and immunogenicity of gelatin‐free varicella vaccine in epidemiological and serological studies in Japan. Vaccine (2005); 23: 1205.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><extent unit="pages"><start>1205</start></extent></part><relatedItem type="host"><titleInfo><title>Vaccine</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><extent unit="pages"><start>1205</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit90"><titleInfo><title>Hydroxychloroquine, hydroxyurea and didanosine as initial therapy for HIV‐infected patients with low viral load: Safety, efficacy and resistance profile after 144 weeks</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Paton NI, Aboulhab J. Hydroxychloroquine, hydroxyurea and didanosine as initial therapy for HIV‐infected patients with low viral load: Safety, efficacy and resistance profile after 144 weeks. HIV Med (2005); 6: 13.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>6</number></detail><extent unit="pages"><start>13</start></extent></part><relatedItem type="host"><titleInfo><title>HIV Med</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>6</number></detail><extent unit="pages"><start>13</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit91"><titleInfo><title>Liposomal amphotericin B and HIV‐associated visceral leishmaniasis ‐ Concerns about nephrotoxicity and administration schedule (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Sabbatani S, Manfredi R, Marinacci G, Pavoni M, Nafissi M, Chiodo F. Liposomal amphotericin B and HIV‐associated visceral leishmaniasis ‐ Concerns about nephrotoxicity and administration schedule (Letter). Clin Drug Invest (2005); 25: 85.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>85</start></extent></part><relatedItem type="host"><titleInfo><title>Clin Drug Invest</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>85</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit92"><titleInfo><title>The safety of interferon‐γ‐1b therapy for invasive fungal infections after hematopoietic stem cell transplantation</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Safdar A, Rodriguez G, Ohmagari N, Kontoyiannis DP, Rolston KV, Raad II, Champlin RE. The safety of interferon‐γ‐1b therapy for invasive fungal infections after hematopoietic stem cell transplantation. Cancer (2005); 103: 731.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>103</number></detail><extent unit="pages"><start>731</start></extent></part><relatedItem type="host"><titleInfo><title>Cancer</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>103</number></detail><extent unit="pages"><start>731</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit93"><titleInfo><title>Ertapenem‐associated seizures in a peritoneal dialysis patient</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Seto AH, Song JC, Guest SS. Ertapenem‐associated seizures in a peritoneal dialysis patient. Ann Pharmacother (2005); 39: 352.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>352</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Pharmacother</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>352</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit94"><titleInfo><title>Acute ulcerative colitis during successful interferon/ribavirin treatment for chronic hepatitis (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Sprenger R, Sagmeister M, Offner F. Acute ulcerative colitis during successful interferon/ribavirin treatment for chronic hepatitis (Letter). Gut (2005); 54: 438.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>54</number></detail><extent unit="pages"><start>438</start></extent></part><relatedItem type="host"><titleInfo><title>Gut</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>54</number></detail><extent unit="pages"><start>438</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit95"><titleInfo><title>Adverse reactions to human rabies immune globulin manufactured by the Thai Red Cross Society</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Suwansrinon K, Jaijaroensup W, Daviratanasilpa S, Sriaroon C, Wilde H, Sitprija V. Adverse reactions to human rabies immune globulin manufactured by the Thai Red Cross Society. Vaccine (2005); 23: 1324.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><extent unit="pages"><start>1324</start></extent></part><relatedItem type="host"><titleInfo><title>Vaccine</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><extent unit="pages"><start>1324</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit96"><titleInfo><title>Serious psychiatric symptoms after chloroquine treatment following experimental malaria infection</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Telgt DS, Van der Ven AJ, Schimmer B, Droogleever‐Fortuyn HA, Sauerwein RW. Serious psychiatric symptoms after chloroquine treatment following experimental malaria infection. Ann Pharmacother (2005); 39: 551.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>551</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Pharmacother</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>551</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit97"><titleInfo><title>Acute ulcerative colitis during successful interferon/ribavirin treatment for chronic hepatitis (Reply)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Tilg H, Reinisch W. Acute ulcerative colitis during successful interferon/ribavirin treatment for chronic hepatitis (Reply). Gut (2005); 54: 439.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>54</number></detail><extent unit="pages"><start>439</start></extent></part><relatedItem type="host"><titleInfo><title>Gut</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>54</number></detail><extent unit="pages"><start>439</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit98"><titleInfo><title>Painful peripheral neuropathy associated with voriconazole use</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Tsiodras S, Zafiropoulou R, Kanta E, Demponeras C, Karandreas N, Manesis EK. Painful peripheral neuropathy associated with voriconazole use. Arch Neurol (2005); 62: 144.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>62</number></detail><extent unit="pages"><start>144</start></extent></part><relatedItem type="host"><titleInfo><title>Arch Neurol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>62</number></detail><extent unit="pages"><start>144</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit99"><titleInfo><title>Flucloxacillin associated neutropenia in children treated for bone and joint infections</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Van den Boom J, Kristiansen JB, Voss LM, Stott NS. Flucloxacillin associated neutropenia in children treated for bone and joint infections. J Paediatr Child Health (2005); 41: 48.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>41</number></detail><extent unit="pages"><start>48</start></extent></part><relatedItem type="host"><titleInfo><title>J Paediatr Child Health</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>41</number></detail><extent unit="pages"><start>48</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit100"><titleInfo><title>Mefloquine increases the risk of serous psychiatric events during travel abroad: A nationwide case‐control study in the Netherlands</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Van Riemsdijk MA, Sturkenboom MCJM, Pepplinkhuizen L, Stricker BHC. Mefloquine increases the risk of serous psychiatric events during travel abroad: A nationwide case‐control study in the Netherlands. J Clin Psychiatry (2005); 66: 199.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>66</number></detail><extent unit="pages"><start>199</start></extent></part><relatedItem type="host"><titleInfo><title>J Clin Psychiatry</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>66</number></detail><extent unit="pages"><start>199</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit101"><titleInfo><title>Vaccination‐induced autoimmune hepatitis (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Veerappan GR, Mulhall BP, Holtzmuller KC. Vaccination‐induced autoimmune hepatitis (Letter). Dig Dis Sci (2005); 50: 212.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>50</number></detail><extent unit="pages"><start>212</start></extent></part><relatedItem type="host"><titleInfo><title>Dig Dis Sci</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>50</number></detail><extent unit="pages"><start>212</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit102"><titleInfo><title>Lymphadenopathy after BCG vaccination in a child with chronic granulomatous disease</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Vieira AP, Vasconcelos J, Fernandes JC, Antunes H, Basto AS, Macedo C, Zaman A, Santos E, Melo JC, Roos D. Lymphadenopathy after BCG vaccination in a child with chronic granulomatous disease. Pediatr Dermatol (2004); 21: 646.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>21</number></detail><extent unit="pages"><start>646</start></extent></part><relatedItem type="host"><titleInfo><title>Pediatr Dermatol</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>21</number></detail><extent unit="pages"><start>646</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit103"><titleInfo><title>Sudden and unexpected deaths after the administration of hexavalent vaccines (diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, Haemophilus influenzae type b): Is there a signal?</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Von Kries R, Toschke AM, Strassburger K, Kundi M, Kalies H, Nennstiel U, Jorch G, Rosenbauer J, Giani G. Sudden and unexpected deaths after the administration of hexavalent vaccines (diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, Haemophilus influenzae type b): Is there a signal?. Eur J Pediatr (2005); 164: 61.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>164</number></detail><extent unit="pages"><start>61</start></extent></part><relatedItem type="host"><titleInfo><title>Eur J Pediatr</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>164</number></detail><extent unit="pages"><start>61</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit104"><titleInfo><title>Vancomycin‐mediated drug‐induced immune thrombocytopenia (Case Report)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Winteroll S, Kerowgan M, Vahl CF, Leo A. Vancomycin‐mediated drug‐induced immune thrombocytopenia (Case Report). Transfus Med Hemother (2005); 32: 20.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>32</number></detail><extent unit="pages"><start>20</start></extent></part><relatedItem type="host"><titleInfo><title>Transfus Med Hemother</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>32</number></detail><extent unit="pages"><start>20</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit105"><titleInfo><title>4. Cardiovascular System Agents</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit106"><titleInfo><title>Fenofibrate‐induced cirrhosis (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ahmed F, Petrovic L, Rosen E, Gonzalez R, Jacobson IM. Fenofibrate‐induced cirrhosis (Letter). Dig Dis Sci (2005); 50: 312.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>50</number></detail><extent unit="pages"><start>312</start></extent></part><relatedItem type="host"><titleInfo><title>Dig Dis Sci</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>50</number></detail><extent unit="pages"><start>312</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit107"><titleInfo><title>Monitoring cyanide toxicity in patients receiving nitroprusside therapy (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Alaniz C, Watts B. Monitoring cyanide toxicity in patients receiving nitroprusside therapy (Letter). Ann Pharmacother (2005); 39: 388.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>388</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Pharmacother</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>388</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit108"><titleInfo><title>Probable sildenafil (Viagra) induced acute hepatitis in a patient with no other risk factors (Letter) (French)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Balian A, Touati F, Huguenin B, Prevot S, Perlemuter G, Naveau S, Chaput JC. Probable sildenafil (Viagra) induced acute hepatitis in a patient with no other risk factors (Letter) (French). Gastroenterol Clin Biol (2005); 29: 89.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>29</number></detail><extent unit="pages"><start>89</start></extent></part><relatedItem type="host"><titleInfo><title>Gastroenterol Clin Biol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>29</number></detail><extent unit="pages"><start>89</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit109"><titleInfo><title>Hepatotoxicity during rapid intravenous loading with amiodarone: Description of three cases and review of the literature</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Bravo AER, Drewe J, Schlienger RG, Krahenbuhl S, Pargger H, Urnmenhofer W. Hepatotoxicity during rapid intravenous loading with amiodarone: Description of three cases and review of the literature. Crit Care Med (2005); 33: 128.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>33</number></detail><extent unit="pages"><start>128</start></extent></part><relatedItem type="host"><titleInfo><title>Crit Care Med</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>33</number></detail><extent unit="pages"><start>128</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit110"><titleInfo><title>Eptifibatide‐associated acute, profound thrombocytopenia (Case Report)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Coons JC, Barcelona RA, Freedy T, Hagerty MF. Eptifibatide‐associated acute, profound thrombocytopenia (Case Report). Ann Pharmacother (2005); 39: 368.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>368</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Pharmacother</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>368</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit111"><titleInfo><title>Safety and tolerability of bosentan in adults with Eisenmenger physiology</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Gatzoulis MA, Rogers P, Li W, Harries C, Cramer D, Ward S, Mikhail GW, Simon J, Gibbs R. Safety and tolerability of bosentan in adults with Eisenmenger physiology. Int J Cardiol (2005); 98: 147.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>98</number></detail><extent unit="pages"><start>147</start></extent></part><relatedItem type="host"><titleInfo><title>Int J Cardiol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>98</number></detail><extent unit="pages"><start>147</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit112"><titleInfo><title>Unilateral optic neuropathy associated with sildenafil intake (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Gruhn N, Fledelius HC. Unilateral optic neuropathy associated with sildenafil intake (Letter). Acta Ophthalmol Scand (2005); 83: 131.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>83</number></detail><extent unit="pages"><start>131</start></extent></part><relatedItem type="host"><titleInfo><title>Acta Ophthalmol Scand</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>83</number></detail><extent unit="pages"><start>131</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit113"><titleInfo><title>Intravenous amiodarone: Offender or bystander?</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Guglin M. Intravenous amiodarone: Offender or bystander?. Crit Care Med (2005); 33: 245.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>33</number></detail><extent unit="pages"><start>245</start></extent></part><relatedItem type="host"><titleInfo><title>Crit Care Med</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>33</number></detail><extent unit="pages"><start>245</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit114"><titleInfo><title>Case reports of dobutamine‐induced myoclonia in severe renal failure: Potential of emerging pharmacovigilance technologies (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Hauben M, Reich L. Case reports of dobutamine‐induced myoclonia in severe renal failure: Potential of emerging pharmacovigilance technologies (Letter). Nephrol Dial Transplant (2005); 20: 471.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><extent unit="pages"><start>471</start></extent></part><relatedItem type="host"><titleInfo><title>Nephrol Dial Transplant</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><extent unit="pages"><start>471</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit115"><titleInfo><title>A case of the toxicity of pilsicainide hydrochloride with comparison of the serial serum pilsicainide levels and electrocardiographic findings</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Horita Y, Kanaya H, Uno Y, Yamazaki T, Kaku B, Funada A, Kitajima S, Matsumura M, Satoh T. A case of the toxicity of pilsicainide hydrochloride with comparison of the serial serum pilsicainide levels and electrocardiographic findings. Jpn Heart J (2004); 45: 1049.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>45</number></detail><extent unit="pages"><start>1049</start></extent></part><relatedItem type="host"><titleInfo><title>Jpn Heart J</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>45</number></detail><extent unit="pages"><start>1049</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit116"><titleInfo><title>Propranolol‐exacerbated mesenteric ischemia in a patient with hyperthyroidism (Case report)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Koksal AS, Uskudar O, Koklu S, Yuksel O, Beyazit Y, Sahin B. Propranolol‐exacerbated mesenteric ischemia in a patient with hyperthyroidism (Case report). Ann Pharmacother (2005); 39: 559.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>559</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Pharmacother</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>559</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit117"><titleInfo><title>Safety of coronary stenting with eptifibatide and ultra‐low‐dose heparin</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Le May M, Kurdi M, Labinaz M, Glover C, So D, Ryan S, Davies R. Safety of coronary stenting with eptifibatide and ultra‐low‐dose heparin. Am J Cardiol (2005); 95: 630.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>95</number></detail><extent unit="pages"><start>630</start></extent></part><relatedItem type="host"><titleInfo><title>Am J Cardiol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>95</number></detail><extent unit="pages"><start>630</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit118"><titleInfo><title>Efficacy and safety of coadministration of ezetimibe and statins in elderly patients with primary hypercholesterolaemia</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Lipka L, Sager P, Strony J, Yang B, Suresh R, Veltri E. Efficacy and safety of coadministration of ezetimibe and statins in elderly patients with primary hypercholesterolaemia. Drugs Aging (2004); 21: 1025.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>21</number></detail><extent unit="pages"><start>1025</start></extent></part><relatedItem type="host"><titleInfo><title>Drugs Aging</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>21</number></detail><extent unit="pages"><start>1025</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit119"><titleInfo><title>Efficacy and safety of molsidomine once‐a‐day in patients with stable angina pectoris</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Messin R, Opolski G, Fenyvesi T, Carreer‐Bruhwyler F, Dubois C, Famaey JP, Geczy J. Efficacy and safety of molsidomine once‐a‐day in patients with stable angina pectoris. Int J Cardiol (2005); 98: 79.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>98</number></detail><extent unit="pages"><start>79</start></extent></part><relatedItem type="host"><titleInfo><title>Int J Cardiol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>98</number></detail><extent unit="pages"><start>79</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit120"><titleInfo><title>Rhabdomyolysis after simvastatin therapy in an HIV‐infected patient with chronic renal failure</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Moro H, Tsukada H, Tanuma A, Shirasaki A, Iino N, Nishibori T, Nishi S, Gejyo F. Rhabdomyolysis after simvastatin therapy in an HIV‐infected patient with chronic renal failure. AIDS Patient Care STDS (2004); 18: 687.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>687</start></extent></part><relatedItem type="host"><titleInfo><title>AIDS Patient Care STDS</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>687</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit121"><titleInfo><title>No evidence for severe retinopathy of prematurity following sildenafil</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Pierce CM, Petros AJ, Fielder AR. No evidence for severe retinopathy of prematurity following sildenafil. Br J Ophthalmol (2005); 89: 250.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>89</number></detail><extent unit="pages"><start>250</start></extent></part><relatedItem type="host"><titleInfo><title>Br J Ophthalmol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>89</number></detail><extent unit="pages"><start>250</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit122"><titleInfo><title>Verapamil toxicity resulting from a probable interaction with telithromycin (Case Report)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Reed M, Wall GC, Shah NP, Heun JM, Hicklin GA. Verapamil toxicity resulting from a probable interaction with telithromycin (Case Report). Ann Pharmacother (2005); 39: 357.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>357</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Pharmacother</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>357</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit123"><titleInfo><title>The myopathy of statins</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Smogorzewski M. The myopathy of statins. J Ren Nutr (2005); 15: 87.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>15</number></detail><extent unit="pages"><start>87</start></extent></part><relatedItem type="host"><titleInfo><title>J Ren Nutr</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>15</number></detail><extent unit="pages"><start>87</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit124"><titleInfo><title>Efficacy and safety of vardenafil in patients with erectile dysfunction. Results of the Mexican multicentric study (Spanish, English Abstract)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Sotomayor‐de‐Zavaleta M, Rubio‐Aurioles E, Feria‐Bernal G, Mendoza‐Valdes A, Quinzanos‐Sordo LF, Ugarte‐y‐Romano F, Hurtado‐Coll A, Telich‐Vidal M, Barreto‐Fernandez MA, Tapia‐Serrano MR, Ureta‐Sanchez SE, Jaspersen‐Gastelum J, Pacheco‐Gahbler C, Senties‐Hernandez IR, Olguin J, Perez‐Garcia J. Efficacy and safety of vardenafil in patients with erectile dysfunction. Results of the Mexican multicentric study (Spanish, English Abstract). Rev Invest Clin (2004); 56: 572.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>56</number></detail><extent unit="pages"><start>572</start></extent></part><relatedItem type="host"><titleInfo><title>Rev Invest Clin</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>56</number></detail><extent unit="pages"><start>572</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit125"><titleInfo><title>Post‐marketing surveillance study of the safety and efficacy of sildenafil prescribed in primary care to erectile dysfunction patients</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Sunwoo S, Kim YS, Cho BL, Cheon KS, Seo HG, Rho MK, Cheong YS, Hong MH, Kim SW, Kim DH. Post‐marketing surveillance study of the safety and efficacy of sildenafil prescribed in primary care to erectile dysfunction patients. Int J Impot Res (2005); 17: 71.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>17</number></detail><extent unit="pages"><start>71</start></extent></part><relatedItem type="host"><titleInfo><title>Int J Impot Res</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>17</number></detail><extent unit="pages"><start>71</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit126"><titleInfo><title>Exertion‐induced rhabdomyolysis in a patient on statin therapy (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Unnikrishnan D, Satish B. Exertion‐induced rhabdomyolysis in a patient on statin therapy (Letter). Nephrol Dial Transplant (2005); 20: 244.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><extent unit="pages"><start>244</start></extent></part><relatedItem type="host"><titleInfo><title>Nephrol Dial Transplant</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><extent unit="pages"><start>244</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit127"><titleInfo><title>Rhabdomyolsis secondary to statin‐macrolide interaction in a kidney recipient (Letter) (Spanish)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Valero R, Rodrigo E, Zubimendi JA, Arias M. Rhabdomyolsis secondary to statin‐macrolide interaction in a kidney recipient (Letter) (Spanish). Nefrologia (2004); 24: 382.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>24</number></detail><extent unit="pages"><start>382</start></extent></part><relatedItem type="host"><titleInfo><title>Nefrologia</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>24</number></detail><extent unit="pages"><start>382</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit128"><titleInfo><title>New‐onset bronchial asthma induced by low‐dose amiodarone</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Yavuzgil O, Goksel T, Gurgun C, Hasdemir C. New‐onset bronchial asthma induced by low‐dose amiodarone. Ann Pharmacother (2005); 39: 385.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>385</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Pharmacother</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>385</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit129"><titleInfo><title>5. CNS Depressive Agents</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit130"><titleInfo><title>Delayed hypersensitivity due to epidural block with ropivacaine</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ban M, Hattori M. Delayed hypersensitivity due to epidural block with ropivacaine. Br Med J (2005); 330: 229.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>330</number></detail><extent unit="pages"><start>229</start></extent></part><relatedItem type="host"><titleInfo><title>Br Med J</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>330</number></detail><extent unit="pages"><start>229</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit131"><titleInfo><title>Fatal hepatic failure and valproate (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Bauer MS. Fatal hepatic failure and valproate (Letter). Am J Psychiatry (2005); 162: 192.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>162</number></detail><extent unit="pages"><start>192</start></extent></part><relatedItem type="host"><titleInfo><title>Am J Psychiatry</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>162</number></detail><extent unit="pages"><start>192</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit132"><titleInfo><title>Hypogeusia as an adverse reaction of phenytoin (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Baumann CR, Ott PM, Siegel AM. Hypogeusia as an adverse reaction of phenytoin (Letter). Br J Clin Pharmacol (2004); 58: 678.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>58</number></detail><extent unit="pages"><start>678</start></extent></part><relatedItem type="host"><titleInfo><title>Br J Clin Pharmacol</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>58</number></detail><extent unit="pages"><start>678</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit133"><titleInfo><title>Safety and efficacy of two pregabalin regimens for add‐on treatment of partial epilepsy</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Beydoun A, Uthman BM, Kugler AR, Greiner MJ, Knapp LE, Garofalo EA. Safety and efficacy of two pregabalin regimens for add‐on treatment of partial epilepsy. Neurology (2005); 64: 475.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>64</number></detail><extent unit="pages"><start>475</start></extent></part><relatedItem type="host"><titleInfo><title>Neurology</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>64</number></detail><extent unit="pages"><start>475</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit134"><titleInfo><title>Dose‐dependent safety and efficacy of zonisamide: A randomized, double‐blind, placebo‐controlled study in patients with refractory partial seizures</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Brodie MJ, Duncan T, Vespignani H, Solyom A, Bitenskyy V, Lucas C. Dose‐dependent safety and efficacy of zonisamide: A randomized, double‐blind, placebo‐controlled study in patients with refractory partial seizures. Epilepsia (2005); 46: 31.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>31</start></extent></part><relatedItem type="host"><titleInfo><title>Epilepsia</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>31</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit135"><titleInfo><title>Acute seizures due to a probable interaction between valproic acid and meropenem (Case Report)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Coves‐Orts FJ, Borras‐Blasco J, Navarro‐Ruiz A, Murcia‐Lopez A, Palacios‐Ortega F. Acute seizures due to a probable interaction between valproic acid and meropenem (Case Report). Ann Pharmacother (2005); 39: 533.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>533</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Pharmacother</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>533</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit136"><titleInfo><title>Phenytoin intoxication in critically ill patients (Case Reports)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">De Schoenmakere G, De Waele J, Terryn W, Deweweire M, Verstraete A, Hoste E, Rottey S, Lameire N, Colardyn F. Phenytoin intoxication in critically ill patients (Case Reports). Am J Kidney Dis (2005); 45: 189.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>45</number></detail><extent unit="pages"><start>189</start></extent></part><relatedItem type="host"><titleInfo><title>Am J Kidney Dis</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>45</number></detail><extent unit="pages"><start>189</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit137"><titleInfo><title>Topiramate and metabolic acidosis: A case series and review of the literature</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Groeper K, McCann ME. Topiramate and metabolic acidosis: A case series and review of the literature. Pediatr Anaesth (2005); 15: 167.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>15</number></detail><extent unit="pages"><start>167</start></extent></part><relatedItem type="host"><titleInfo><title>Pediatr Anaesth</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>15</number></detail><extent unit="pages"><start>167</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit138"><titleInfo><title>Valproate‐induced hyperammonemic encephalopathy: Imaging findings on diffusion‐weighted MRI</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Grubben B, De Jonghe P, Cras P, Demey HE, Parizel PM. Valproate‐induced hyperammonemic encephalopathy: Imaging findings on diffusion‐weighted MRI. Eur Neurol (2004); 52: 178.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>52</number></detail><extent unit="pages"><start>178</start></extent></part><relatedItem type="host"><titleInfo><title>Eur Neurol</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>52</number></detail><extent unit="pages"><start>178</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit139"><titleInfo><title>Efficacy, safety, and steady‐state pharmacokinetics of once‐a‐day controlled‐release morphine (MS Contin XL®) in cancer pain</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Hagen NA, Thirlwell M, Eisenhoffer J, Quigley P, Harsanyi Z, Darke A. Efficacy, safety, and steady‐state pharmacokinetics of once‐a‐day controlled‐release morphine (MS Contin XL®) in cancer pain. J Pain Symptom Manage (2005); 29: 80.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>29</number></detail><extent unit="pages"><start>80</start></extent></part><relatedItem type="host"><titleInfo><title>J Pain Symptom Manage</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>29</number></detail><extent unit="pages"><start>80</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit140"><titleInfo><title>Reduced visual function associated with infantile spasms in children on vigabatrin therapy</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Hammoudi DS, Lee SSF, Madison A, Mirabella G, Buncic JR, Logan WJ, Snead OC, Westall CA. Reduced visual function associated with infantile spasms in children on vigabatrin therapy. Invest Ophthalmol Vis Sci (2005); 46: 514.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>514</start></extent></part><relatedItem type="host"><titleInfo><title>Invest Ophthalmol Vis Sci</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>514</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit141"><titleInfo><title>Erectile dysfunction with topiramate (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Holtkamp M, Weissinger F, Meierkord H. Erectile dysfunction with topiramate (Letter). Epilepsia (2005); 46: 166.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>166</start></extent></part><relatedItem type="host"><titleInfo><title>Epilepsia</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>166</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit142"><titleInfo><title>Recurrent severe aseptic meningitis after exposure to lamotrigine in a patient with systemic lupus erythematosus (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kilfoyle DH, Anderson NE, Wallis WE, Nicholls DW. Recurrent severe aseptic meningitis after exposure to lamotrigine in a patient with systemic lupus erythematosus (Letter). Epilepsia (2005); 46: 327.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>327</start></extent></part><relatedItem type="host"><titleInfo><title>Epilepsia</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>327</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit143"><titleInfo><title>Valproic acid‐associated hyperammonemic encephalopathy: A case report from the psychiatric setting</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kimmel RJ, Irwin SA, Meyer JM. Valproic acid‐associated hyperammonemic encephalopathy: A case report from the psychiatric setting. Int Clin Psychopharmacol (2005); 20: 57.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><extent unit="pages"><start>57</start></extent></part><relatedItem type="host"><titleInfo><title>Int Clin Psychopharmacol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><extent unit="pages"><start>57</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit144"><titleInfo><title>Tramadol and new‐onset seizures (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Labate A, Newton MR, Vernon GM, Berkovic SF. Tramadol and new‐onset seizures (Letter). Med J Aust (2005); 182: 42.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>182</number></detail><extent unit="pages"><start>42</start></extent></part><relatedItem type="host"><titleInfo><title>Med J Aust</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>182</number></detail><extent unit="pages"><start>42</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit145"><titleInfo><title>Methemoglobinemia secondary to topical benzocaine use in a lung transplant patient (Case Report)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">LeClaire AC, Mullett TW, Jahania MS, Flynn JD. Methemoglobinemia secondary to topical benzocaine use in a lung transplant patient (Case Report). Ann Pharmacother (2005); 39: 373.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>373</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Pharmacother</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>373</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit146"><titleInfo><title>Efficacy and safety of three ophthalmic inserts for topical anaesthesia of the cornea. An exploratory comparative dose‐ranging, double‐blind, randomized trial in healthy volunteers</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Mahe I, Mouly S, Jarrin I, Otero J, Tavera C, Simoneau G, Tillet Y, Conti R, El Meski S, Gaudric A, Bergmann JF. Efficacy and safety of three ophthalmic inserts for topical anaesthesia of the cornea. An exploratory comparative dose‐ranging, double‐blind, randomized trial in healthy volunteers. Br J Clin Pharmacol (2005); 59: 220.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>59</number></detail><extent unit="pages"><start>220</start></extent></part><relatedItem type="host"><titleInfo><title>Br J Clin Pharmacol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>59</number></detail><extent unit="pages"><start>220</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit147"><titleInfo><title>Anaphylactic and anaphylactoid reactions occurring during anaesthesia in France, Seventh epidemiological survey (January 2001‐December 2002) (French, English Abstract)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Mertes PM, Laxenaire MC. Anaphylactic and anaphylactoid reactions occurring during anaesthesia in France, Seventh epidemiological survey (January 2001‐December 2002) (French, English Abstract). Ann Fr Anesth Reanim (2004); 23: 1133.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><extent unit="pages"><start>1133</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Fr Anesth Reanim</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><extent unit="pages"><start>1133</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit148"><titleInfo><title>Topiramate related obsessive‐compulsive disorder (Case Report)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ozkara C, Ozmen M, Erdogan A, Yalug I. Topiramate related obsessive‐compulsive disorder (Case Report). Eur Psychiatry (2005); 20: 78.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><extent unit="pages"><start>78</start></extent></part><relatedItem type="host"><titleInfo><title>Eur Psychiatry</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><extent unit="pages"><start>78</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit149"><titleInfo><title>Lamotrigine‐induced rash ‐ Worth a rechallenge</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">P‐Codrea S, Sidenius P, Dam M. Lamotrigine‐induced rash ‐ Worth a rechallenge. Acta Neurol Scand (2005); 111: 191.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>111</number></detail><extent unit="pages"><start>191</start></extent></part><relatedItem type="host"><titleInfo><title>Acta Neurol Scand</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>111</number></detail><extent unit="pages"><start>191</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit150"><titleInfo><title>Dystonia induced by gabapentin (Case Report)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Pina MA, Modrego PJ. Dystonia induced by gabapentin (Case Report). Ann Pharmacother (2005); 39: 380.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>380</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Pharmacother</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>380</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit151"><titleInfo><title>Computerized tremor analysis of valproate‐induced tremor: A comparative study of controlled‐release versus conventional valproate</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Rinnerthaler M, Luef G, Mueller J, Seppi K, Wissel J, Trinka E, Bauer G, Poewe W. Computerized tremor analysis of valproate‐induced tremor: A comparative study of controlled‐release versus conventional valproate. Epilepsia (2005); 46: 320.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>320</start></extent></part><relatedItem type="host"><titleInfo><title>Epilepsia</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>320</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit152"><titleInfo><title>Effectiveness and safety of oral extended‐release oxymorphone for the treatment of cancer pain: A pilot study</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Sloan P, Slatkin N, Ahdieh H. Effectiveness and safety of oral extended‐release oxymorphone for the treatment of cancer pain: A pilot study. Support Care Cancer (2005); 13: 57.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>13</number></detail><extent unit="pages"><start>57</start></extent></part><relatedItem type="host"><titleInfo><title>Support Care Cancer</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>13</number></detail><extent unit="pages"><start>57</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit153"><titleInfo><title>Cerebral blood flow velocity increases when propofol is changed to desflurane, but not when isoflurane is changed to desflurane in children</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Smith JH, Karsli C, Lagace A, Luginbuehl I, Barlow R, Bissonnette B. Cerebral blood flow velocity increases when propofol is changed to desflurane, but not when isoflurane is changed to desflurane in children. Acta Anaesthesiol Scand (2005); 49: 23.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>49</number></detail><extent unit="pages"><start>23</start></extent></part><relatedItem type="host"><titleInfo><title>Acta Anaesthesiol Scand</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>49</number></detail><extent unit="pages"><start>23</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit154"><titleInfo><title>Unilateral bronchospasm following interpleural analgesia with bupivacaine (Case Reports)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Sudhakar S, Kundra P, Madhurima S, Ravishankar M. Unilateral bronchospasm following interpleural analgesia with bupivacaine (Case Reports). Acta Anaesthesiol Scand (2005); 49: 104.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>49</number></detail><extent unit="pages"><start>104</start></extent></part><relatedItem type="host"><titleInfo><title>Acta Anaesthesiol Scand</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>49</number></detail><extent unit="pages"><start>104</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit155"><titleInfo><title>Acute acetaminophen in toxication in Taiwan outcomes and risk factors</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Tsai CL, Chang WT, Weng TI, Fang CC, Chen WJ. Acute acetaminophen in toxication in Taiwan outcomes and risk factors. J Formos Med Assoc (2004); 103: 830.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>103</number></detail><extent unit="pages"><start>830</start></extent></part><relatedItem type="host"><titleInfo><title>J Formos Med Assoc</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>103</number></detail><extent unit="pages"><start>830</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit156"><titleInfo><title>Intrathecal midazolam: Adverse effects and sources of bias (Response)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Tucker AP, Mezzatesta J, Nadeson R, Goodchild CS. Intrathecal midazolam: Adverse effects and sources of bias (Response). Anesth Analg (2005); 100: 605.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>100</number></detail><extent unit="pages"><start>605</start></extent></part><relatedItem type="host"><titleInfo><title>Anesth Analg</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>100</number></detail><extent unit="pages"><start>605</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit157"><titleInfo><title>Intrathecal midazolam: Adverse effects and sources of bias (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Walker L. Intrathecal midazolam: Adverse effects and sources of bias (Letter). Anesth Analg (2005); 100: 604.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>100</number></detail><extent unit="pages"><start>604</start></extent></part><relatedItem type="host"><titleInfo><title>Anesth Analg</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>100</number></detail><extent unit="pages"><start>604</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit158"><titleInfo><title>Gabapentin‐induced myoclonus in end‐stage renal disease</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Zhang CX, Glenn DG, Bell WL, O'Donovan CA. Gabapentin‐induced myoclonus in end‐stage renal disease. Epilepsia (2005); 46: 156.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>156</start></extent></part><relatedItem type="host"><titleInfo><title>Epilepsia</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>156</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit159"><titleInfo><title>6. Non‐steroidal Anti‐inflammatory Agents</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit160"><titleInfo><title>Lessons to be learned from the Vioxx debacle (Editorial)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Beller GA. Lessons to be learned from the Vioxx debacle (Editorial). J Nucl Cardiol (2005); 12: 1.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>12</number></detail><extent unit="pages"><start>1</start></extent></part><relatedItem type="host"><titleInfo><title>J Nucl Cardiol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>12</number></detail><extent unit="pages"><start>1</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit161"><titleInfo><title>Vioxx and cardiovascular events: A class effect? (Editorial)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Berenbaum F. Vioxx and cardiovascular events: A class effect? (Editorial). Joint Bone Spine (2005); 72: 1.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>72</number></detail><extent unit="pages"><start>1</start></extent></part><relatedItem type="host"><titleInfo><title>Joint Bone Spine</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>72</number></detail><extent unit="pages"><start>1</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit162"><titleInfo><title>Cardiovascular risks of coxibs: The orthopaedic perspective (Editorial)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Bhattacharyya T, Smith RM. Cardiovascular risks of coxibs: The orthopaedic perspective (Editorial). J Bone Joint Surg Am (2005); 87A: 245.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>87A</number></detail><extent unit="pages"><start>245</start></extent></part><relatedItem type="host"><titleInfo><title>J Bone Joint Surg Am</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>87A</number></detail><extent unit="pages"><start>245</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit163"><titleInfo><title>Ten lessons to be learned from the withdrawal of Vioxx® (rofecoxib) (Commentary)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Carne X, Cruz N. Ten lessons to be learned from the withdrawal of Vioxx® (rofecoxib) (Commentary). Eur J Epidemiol (2005); 20: 127.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><extent unit="pages"><start>127</start></extent></part><relatedItem type="host"><titleInfo><title>Eur J Epidemiol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><extent unit="pages"><start>127</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit164"><titleInfo><title>Safety and efficacy study on etanercept in patients with plaque psoriasis (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Costanzo A, Mazzotta A, Papoutsaki M, Chimenti S. Safety and efficacy study on etanercept in patients with plaque psoriasis (Letter). Br J Dermatol (2005); 152: 187.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>152</number></detail><extent unit="pages"><start>187</start></extent></part><relatedItem type="host"><titleInfo><title>Br J Dermatol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>152</number></detail><extent unit="pages"><start>187</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit165"><titleInfo><title>Parecoxib, valdecoxib, and cardiovascular risk (Editorial)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Furberg CD, Psaty BM, FitzGerald GA. Parecoxib, valdecoxib, and cardiovascular risk (Editorial). Circulation (2005); 111: 249.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>111</number></detail><extent unit="pages"><start>249</start></extent></part><relatedItem type="host"><titleInfo><title>Circulation</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>111</number></detail><extent unit="pages"><start>249</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit166"><titleInfo><title>Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo‐oxygenase 2 selective and non‐selective non‐steroidal anti‐inflammatory drugs: Nested case‐control study</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Graham DJ, Campen D, Hui R, Spence M, Cheetham C, Levy G, Shoor S, Graham D. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo‐oxygenase 2 selective and non‐selective non‐steroidal anti‐inflammatory drugs: Nested case‐control study. Lancet (2005); 365: 475.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>365</number></detail><extent unit="pages"><start>475</start></extent></part><relatedItem type="host"><titleInfo><title>Lancet</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>365</number></detail><extent unit="pages"><start>475</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit167"><titleInfo><title>Valdecoxib‐induced systemic contact dermatitis confirmed by positive patch test</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Jaeger C, Jappe U. Valdecoxib‐induced systemic contact dermatitis confirmed by positive patch test. Contact Dermatitis (2005); 52: 47.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>52</number></detail><extent unit="pages"><start>47</start></extent></part><relatedItem type="host"><titleInfo><title>Contact Dermatitis</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>52</number></detail><extent unit="pages"><start>47</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit168"><titleInfo><title>A randomised, placebo controlled, comparative trial of the gastrointestinal safety and efficacy of AZD3582 versus naproxen in osteoarthritis</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Lohmander LS, McKeith D, Svensson O, Malmenas M, Bolin L, Kalla A, Genti G, Szechinski J, Ramos‐Remus C. A randomised, placebo controlled, comparative trial of the gastrointestinal safety and efficacy of AZD3582 versus naproxen in osteoarthritis. Ann Rheum Dis (2005); 64: 449.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>64</number></detail><extent unit="pages"><start>449</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Rheum Dis</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>64</number></detail><extent unit="pages"><start>449</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit169"><titleInfo><title>Severe bronchospasm after parenteral parecoxib: Cyclooxygenase‐2 inhibitors: Not the answer yet (Case Report)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Looney Y, O'Shea A, O'Dwyer R. Severe bronchospasm after parenteral parecoxib: Cyclooxygenase‐2 inhibitors: Not the answer yet (Case Report). Anesthesiology (2005); 102: 473.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>102</number></detail><extent unit="pages"><start>473</start></extent></part><relatedItem type="host"><titleInfo><title>Anesthesiology</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>102</number></detail><extent unit="pages"><start>473</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit170"><titleInfo><title>DRESS syndrome in a patient on sulfasalazine for rheumatoid arthritis (Case Report)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Michel F, Navellou JC, Ferraud D, Toussirot E, Wendling D. DRESS syndrome in a patient on sulfasalazine for rheumatoid arthritis (Case Report). Joint Bone Spine (2005); 72: 82.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>72</number></detail><extent unit="pages"><start>82</start></extent></part><relatedItem type="host"><titleInfo><title>Joint Bone Spine</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>72</number></detail><extent unit="pages"><start>82</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit171"><titleInfo><title>Short‐term and long‐term tolerability of rofecoxib in patients with prior reactions to nonsteroidal anti‐inflammatory drugs</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Nettis E, Colanardi MC, Ferrannini A, Tursi A. Short‐term and long‐term tolerability of rofecoxib in patients with prior reactions to nonsteroidal anti‐inflammatory drugs. Ann Allergy Asthma Immunol (2005); 94: 29.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>94</number></detail><extent unit="pages"><start>29</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Allergy Asthma Immunol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>94</number></detail><extent unit="pages"><start>29</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit172"><titleInfo><title>A randomized, double‐blind clinical trial of two doses of meloxicam compared with naproxen in children with juvenile idiopathic arthritis ‐ Short and long‐term efficacy and safety results</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ruperto N, Nikishina I, Pachanov ED, Shachbazian Y, Prieur AM, Mouy R, Joos R, Zulian F, Schwarz R, Artamonova V, Emminger W, Bandeira M, Buoncompagni A, Foeldvari I, Falcini F, Baildam E, Kone‐Paut I, Alessio M, Gerloni V, Lenhardt A, Martini A, Hanft G, Sigmund R, Simianer S. A randomized, double‐blind clinical trial of two doses of meloxicam compared with naproxen in children with juvenile idiopathic arthritis ‐ Short and long‐term efficacy and safety results. Arthritis Rheum (2005); 52: 563.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>52</number></detail><extent unit="pages"><start>563</start></extent></part><relatedItem type="host"><titleInfo><title>Arthritis Rheum</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>52</number></detail><extent unit="pages"><start>563</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit173"><titleInfo><title>Tolerance of nonsteroidal anti‐inflammatory drug‐sensitive patients to the highly specific cyclooxygenase 2 inhibitors rofecoxib and valdecoxib</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Sanchez‐Borges M, Caballero‐Fonseca F, Capriles‐Hulett A. Tolerance of nonsteroidal anti‐inflammatory drug‐sensitive patients to the highly specific cyclooxygenase 2 inhibitors rofecoxib and valdecoxib. Ann Allergy Asthma Immunol (2005); 94: 34.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>94</number></detail><extent unit="pages"><start>34</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Allergy Asthma Immunol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>94</number></detail><extent unit="pages"><start>34</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit174"><titleInfo><title>The multiple faces of nonsteroidal antiinflammatory drug hypersensitivity</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Sanchez‐Borges M, Capriles‐Hulett A, Caballero‐Fonseca F. The multiple faces of nonsteroidal antiinflammatory drug hypersensitivity. J Investig Allerg Clin Immunol (2004); 14: 329.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>14</number></detail><extent unit="pages"><start>329</start></extent></part><relatedItem type="host"><titleInfo><title>J Investig Allerg Clin Immunol</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>14</number></detail><extent unit="pages"><start>329</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit175"><titleInfo><title>Cross‐reactivity of cyclooxygenase 2 inhibitors in patients with a history of cutaneous reactions to cyclooxygenase 1 inhibitors (Editorial)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Simon RA, Stevenson DD. Cross‐reactivity of cyclooxygenase 2 inhibitors in patients with a history of cutaneous reactions to cyclooxygenase 1 inhibitors (Editorial). Ann Allergy Asthma Immunol (2005); 94: 8.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>94</number></detail><extent unit="pages"><start>8</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Allergy Asthma Immunol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>94</number></detail><extent unit="pages"><start>8</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit176"><titleInfo><title>Use of gastroprotective agents and discontinuations due to dyspepsia with the selective cyclooxygenase‐2 inhibitor etoricoxib compared with non‐selective NSAIDs</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Watson DJ, Bolognese JA, Yu C, Krupa D, Curtis S. Use of gastroprotective agents and discontinuations due to dyspepsia with the selective cyclooxygenase‐2 inhibitor etoricoxib compared with non‐selective NSAIDs. Curr Med Res Opin (2004); 20: 1899.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><extent unit="pages"><start>1899</start></extent></part><relatedItem type="host"><titleInfo><title>Curr Med Res Opin</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><extent unit="pages"><start>1899</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit177"><titleInfo><title>The lessons of Vioxx® (Editorial)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Weinberg JM. The lessons of Vioxx® (Editorial). Cutis (2005); 75: 17.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>75</number></detail><extent unit="pages"><start>17</start></extent></part><relatedItem type="host"><titleInfo><title>Cutis</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>75</number></detail><extent unit="pages"><start>17</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit178"><titleInfo><title>7. CNS Agents</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit179"><titleInfo><title>Is it worth while changing clinically stable schizophrenic out‐patients with mild to moderate residual symptoms and/or side effects from conventional to atypical antipsychotics? A prospective, randomised study with olanzapine</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Appelberg B, Tuisku K, Joffe G. Is it worth while changing clinically stable schizophrenic out‐patients with mild to moderate residual symptoms and/or side effects from conventional to atypical antipsychotics? A prospective, randomised study with olanzapine. Eur Psychiatry (2004); 19: 516.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>19</number></detail><extent unit="pages"><start>516</start></extent></part><relatedItem type="host"><titleInfo><title>Eur Psychiatry</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>19</number></detail><extent unit="pages"><start>516</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit180"><titleInfo><title>Improvement of dry mouth by replacing paroxetine with fluvoxamine (Case Report)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Arima Y, Kubo C, Tsujimoto M, Ohtani H, Sawada Y. Improvement of dry mouth by replacing paroxetine with fluvoxamine (Case Report). Ann Pharmacother (2005); 39: 567.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>567</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Pharmacother</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>567</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit181"><titleInfo><title>Clozapine‐induced stuttering, facial tics and myoclonic seizures: A case report</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Begum M. Clozapine‐induced stuttering, facial tics and myoclonic seizures: A case report. Aust N Z J Psychiatry (2005); 39: 202.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>202</start></extent></part><relatedItem type="host"><titleInfo><title>Aust N Z J Psychiatry</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>202</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit182"><titleInfo><title>Antipsychotic treatment and sexual functioning in first‐time neuroleptic‐treated schizophrenic patients</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Bitter I, Basson BR, Dossenbach MR. Antipsychotic treatment and sexual functioning in first‐time neuroleptic‐treated schizophrenic patients. Int Clin Psychopharmacol (2005); 20: 19.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><extent unit="pages"><start>19</start></extent></part><relatedItem type="host"><titleInfo><title>Int Clin Psychopharmacol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><extent unit="pages"><start>19</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit183"><titleInfo><title>A case of complex movement disorder induced by fluoxetine with management of dystonia by botulinum toxin type A (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Chen JJ, Swope DM. A case of complex movement disorder induced by fluoxetine with management of dystonia by botulinum toxin type A (Letter). J Clin Psychiatry (2005); 66: 267.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>66</number></detail><extent unit="pages"><start>267</start></extent></part><relatedItem type="host"><titleInfo><title>J Clin Psychiatry</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>66</number></detail><extent unit="pages"><start>267</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit184"><titleInfo><title>Comparative efficacy and safety of long‐acting risperidone and risperidone oral tablets</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Chue P, Eerdekens M, Augustyns I, Lachaux B, Molcan P, Eriksson L, Pretorius H, David AS. Comparative efficacy and safety of long‐acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol (2005); 15: 111.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>15</number></detail><extent unit="pages"><start>111</start></extent></part><relatedItem type="host"><titleInfo><title>Eur Neuropsychopharmacol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>15</number></detail><extent unit="pages"><start>111</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit185"><titleInfo><title>Suicide, depression, and antidepressants ‐ Patients and clinicians need to balance benefits and harms (Editorial)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Cipriani A, Barbui C, Geddes JR. Suicide, depression, and antidepressants ‐ Patients and clinicians need to balance benefits and harms (Editorial). Br Med J (2005); 330: 373.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>330</number></detail><extent unit="pages"><start>373</start></extent></part><relatedItem type="host"><titleInfo><title>Br Med J</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>330</number></detail><extent unit="pages"><start>373</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit186"><titleInfo><title>Diabetes mellitus during olanzapine and quetiapine treatment in Japan (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Cohen D. Diabetes mellitus during olanzapine and quetiapine treatment in Japan (Letter). J Clin Psychiatry (2005); 66: 265.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>66</number></detail><extent unit="pages"><start>265</start></extent></part><relatedItem type="host"><titleInfo><title>J Clin Psychiatry</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>66</number></detail><extent unit="pages"><start>265</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit187"><titleInfo><title>Adolescent weight loss during treatment with olanzapine</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Cohen JA, Perel JM. Adolescent weight loss during treatment with olanzapine. J Child Adolesc Psychopharmacol (2004); 14: 617.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>14</number></detail><extent unit="pages"><start>617</start></extent></part><relatedItem type="host"><titleInfo><title>J Child Adolesc Psychopharmacol</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>14</number></detail><extent unit="pages"><start>617</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit188"><titleInfo><title>Olanzapine‐induced diabetes in a seven‐year‐old boy</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Courvoisie HE, Cooke DW, Riddle MA. Olanzapine‐induced diabetes in a seven‐year‐old boy. J Child Adolesc Psychopharmacol (2004); 14: 612.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>14</number></detail><extent unit="pages"><start>612</start></extent></part><relatedItem type="host"><titleInfo><title>J Child Adolesc Psychopharmacol</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>14</number></detail><extent unit="pages"><start>612</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit189"><titleInfo><title>Amantadine for weight gain associated with olanzapine treatment</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Deberdt W, Winokur A, Cavazzoni PA, Trzaskoma QN, Carlson CD, Bymaster FP, Wiener K, Floris M, Breier A. Amantadine for weight gain associated with olanzapine treatment. Eur Neuropsychopharmacol (2005); 15: 13.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>15</number></detail><extent unit="pages"><start>13</start></extent></part><relatedItem type="host"><titleInfo><title>Eur Neuropsychopharmacol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>15</number></detail><extent unit="pages"><start>13</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit190"><titleInfo><title>Clozapine‐induced toxic hepatitis with skin rash (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Fong SYY, Yeung KLA, Tosh JMY, Wing YK. Clozapine‐induced toxic hepatitis with skin rash (Letter). J Psychopharmacol (2005); 19: 107.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>19</number></detail><extent unit="pages"><start>107</start></extent></part><relatedItem type="host"><titleInfo><title>J Psychopharmacol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>19</number></detail><extent unit="pages"><start>107</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit191"><titleInfo><title>Fluoxetine‐induced changes in tactile sensation and sexual functioning among clinically depressed women</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Frohlich P, Meston CA. Fluoxetine‐induced changes in tactile sensation and sexual functioning among clinically depressed women. J Sex Marital Ther (2005); 31: 113.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>31</number></detail><extent unit="pages"><start>113</start></extent></part><relatedItem type="host"><titleInfo><title>J Sex Marital Ther</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>31</number></detail><extent unit="pages"><start>113</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit192"><titleInfo><title>The relationship between antidepressant medication use and rate of suicide</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Gibbons RD, Hur K, Bhaumik DK, Mann JJ. The relationship between antidepressant medication use and rate of suicide. Arch Gen Psychiatry (2005); 62: 165.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>62</number></detail><extent unit="pages"><start>165</start></extent></part><relatedItem type="host"><titleInfo><title>Arch Gen Psychiatry</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>62</number></detail><extent unit="pages"><start>165</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit193"><titleInfo><title>Induction of the rabbit syndrome following coadministration of paroxetine, perphenazine, and amitriptyline (Case Report)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Gourzis P, Polychronopoulos P, Argyriou AA, Bakalidou C, Beratis S. Induction of the rabbit syndrome following coadministration of paroxetine, perphenazine, and amitriptyline (Case Report). Clin Neuropharmacol (2004); 27: 299.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>299</start></extent></part><relatedItem type="host"><titleInfo><title>Clin Neuropharmacol</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>299</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit194"><titleInfo><title>Effect of olanzapine on body composition and energy expenditure in adults with first‐episode psychosis</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Graham KA, Perkins DO, Edwards LJ, Barrier RC, Lieberman JA, Harp JB. Effect of olanzapine on body composition and energy expenditure in adults with first‐episode psychosis. Am J Psychiatry (2005); 162: 118.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>162</number></detail><extent unit="pages"><start>118</start></extent></part><relatedItem type="host"><titleInfo><title>Am J Psychiatry</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>162</number></detail><extent unit="pages"><start>118</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit195"><titleInfo><title>Current options in the management of olanzapine‐associated weight gain</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Hester EK, Thrower MR. Current options in the management of olanzapine‐associated weight gain. Ann Pharmacother (2005); 39: 302.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>302</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Pharmacother</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>302</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit196"><titleInfo><title>Elevation of liver enzyme levels during psychopharmacological treatment is associated with weight gain</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Himmerich H, Kaufmann C, Schuld A, Pollmacher T. Elevation of liver enzyme levels during psychopharmacological treatment is associated with weight gain. J Psychiatr Res (2005); 39: 35.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>35</start></extent></part><relatedItem type="host"><titleInfo><title>J Psychiatr Res</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>35</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit197"><titleInfo><title>Leukopenia in clozapine treated patients may be induced by other drugs: A case series</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Imbarlina MJ, Sarkar S, Marwah S, Parepally H, Johnston PR, Brar JS, Chengappa KNR. Leukopenia in clozapine treated patients may be induced by other drugs: A case series. Eur Psychiatry (2004); 19: 506.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>19</number></detail><extent unit="pages"><start>506</start></extent></part><relatedItem type="host"><titleInfo><title>Eur Psychiatry</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>19</number></detail><extent unit="pages"><start>506</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit198"><titleInfo><title>Actometry and Barnes Akathisia Rating Scale in neuroleptic‐induced akathisia</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Janno S, Holi MM, Tuisku K, Wahlbeck K. Actometry and Barnes Akathisia Rating Scale in neuroleptic‐induced akathisia. Eur Neuropsychopharmacol (2005); 15: 39.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>15</number></detail><extent unit="pages"><start>39</start></extent></part><relatedItem type="host"><titleInfo><title>Eur Neuropsychopharmacol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>15</number></detail><extent unit="pages"><start>39</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit199"><titleInfo><title>Reversible nocturnal enuresis in children receiving SSRI with or without risperidone: Presentation of five cases</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kandil ST, Aksu HB, Ozyavuz R. Reversible nocturnal enuresis in children receiving SSRI with or without risperidone: Presentation of five cases. Isr J Psychiat Related Sci (2004); 41: 218.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>41</number></detail><extent unit="pages"><start>218</start></extent></part><relatedItem type="host"><titleInfo><title>Isr J Psychiat Related Sci</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>41</number></detail><extent unit="pages"><start>218</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit200"><titleInfo><title>Reversal of antipsychotic‐induced weight gain during quetiapine treatment</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Koponen H, Larmo I. Reversal of antipsychotic‐induced weight gain during quetiapine treatment. Int Clin Psychopharmacol (2003); 18: 355.</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>355</start></extent></part><relatedItem type="host"><titleInfo><title>Int Clin Psychopharmacol</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>355</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit201"><titleInfo><title>A comparison of two novel antipsychotics in first episode non‐affective psychosis: One‐year outcome on symptoms, motor side effects and cognition</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Malla A, Norman R, Scholten D, Townsend L, Manchanda R, Takhar J, Haricharan R. A comparison of two novel antipsychotics in first episode non‐affective psychosis: One‐year outcome on symptoms, motor side effects and cognition. Psychiatry Res (2004); 129: 159.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>129</number></detail><extent unit="pages"><start>159</start></extent></part><relatedItem type="host"><titleInfo><title>Psychiatry Res</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>129</number></detail><extent unit="pages"><start>159</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit202"><titleInfo><title>Antidepressant treatment and the risk of fatal and non‐fatal self harm in first episode depression: Nested case‐control study</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Martinez C, Rietbrock S, Wise L, Ashby D, Chick J, Moseley J, Evans S, Gunnell D. Antidepressant treatment and the risk of fatal and non‐fatal self harm in first episode depression: Nested case‐control study. Br Med J (2005); 330: 389.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>330</number></detail><extent unit="pages"><start>389</start></extent></part><relatedItem type="host"><titleInfo><title>Br Med J</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>330</number></detail><extent unit="pages"><start>389</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit203"><titleInfo><title>Olanzapine‐induced hyperprolactinemia and galactorrhea reversed with addition of bromocriptine: A case report</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Miller DE, Sebastian CS. Olanzapine‐induced hyperprolactinemia and galactorrhea reversed with addition of bromocriptine: A case report. J Clin Psychiatry (2005); 66: 269.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>66</number></detail><extent unit="pages"><start>269</start></extent></part><relatedItem type="host"><titleInfo><title>J Clin Psychiatry</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>66</number></detail><extent unit="pages"><start>269</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit204"><titleInfo><title>Diabetes mellitus during olanzapine and quetiapine treatment in Japan (Rely)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Misawa F, Fujii Y. Diabetes mellitus during olanzapine and quetiapine treatment in Japan (Rely). J Clin Psychiatry (2005); 66: 266.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>66</number></detail><extent unit="pages"><start>266</start></extent></part><relatedItem type="host"><titleInfo><title>J Clin Psychiatry</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>66</number></detail><extent unit="pages"><start>266</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit205"><titleInfo><title>Association between mortality from suicide in England and antidepressant prescribing: An ecological study</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Morgan OWC, Griffiths C, Majeed A. Association between mortality from suicide in England and antidepressant prescribing: An ecological study. BMC Public Health (2004); 4: 63.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>4</number></detail><extent unit="pages"><start>63</start></extent></part><relatedItem type="host"><titleInfo><title>BMC Public Health</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>4</number></detail><extent unit="pages"><start>63</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit206"><titleInfo><title>QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine (Case Report)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Nykamp DL, Blackmon CL, Schmidt PE, Roberson AG. QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine (Case Report). Ann Pharmacother (2005); 39: 543.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>543</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Pharmacother</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>543</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit207"><titleInfo><title>Joint symptoms in patients on bupropion therapy (Case Report)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ornetti P, Disson‐Dautriche A, Muller G, Cherasse A, Tavernier C, Besancenot JF, Sgro C, Maillefert JF. Joint symptoms in patients on bupropion therapy (Case Report). Joint Bone Spine (2004); 71: 583.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>71</number></detail><extent unit="pages"><start>583</start></extent></part><relatedItem type="host"><titleInfo><title>Joint Bone Spine</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>71</number></detail><extent unit="pages"><start>583</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit208"><titleInfo><title>The efficacy and safety of venlafaxine in the prophylaxis of migraine</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ozyalcin SN, Talu GK, Kiziltan E, Yucel B, Ertas M, Disci R. The efficacy and safety of venlafaxine in the prophylaxis of migraine. Headache (2005); 45: 144.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>45</number></detail><extent unit="pages"><start>144</start></extent></part><relatedItem type="host"><titleInfo><title>Headache</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>45</number></detail><extent unit="pages"><start>144</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit209"><titleInfo><title>Seizures associated with memantine use</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Peltz G, Pacific DM, Noviasky JA, Shatla A. Seizures associated with memantine use. Am J Health Syst Pharm (2005); 62: 420.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>62</number></detail><extent unit="pages"><start>420</start></extent></part><relatedItem type="host"><titleInfo><title>Am J Health Syst Pharm</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>62</number></detail><extent unit="pages"><start>420</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit210"><titleInfo><title>Serotonin reuptake inhibitor induced sensory disturbances</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Praharaj SK. Serotonin reuptake inhibitor induced sensory disturbances. Br J Clin Pharmacol (2004); 58: 673.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>58</number></detail><extent unit="pages"><start>673</start></extent></part><relatedItem type="host"><titleInfo><title>Br J Clin Pharmacol</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>58</number></detail><extent unit="pages"><start>673</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit211"><titleInfo><title>Incidence of diabetes in a general practice population: A database cohort study on the relationship with haloperidol, olanzapine, risperidone or quetiapine exposure</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Sacchetti E, Turrina C, Parrinello G, Brignoli O, Stefanini G, Mazzaglia G. Incidence of diabetes in a general practice population: A database cohort study on the relationship with haloperidol, olanzapine, risperidone or quetiapine exposure. Int Clin Psychopharmacol (2005); 20: 33.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><extent unit="pages"><start>33</start></extent></part><relatedItem type="host"><titleInfo><title>Int Clin Psychopharmacol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><extent unit="pages"><start>33</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit212"><titleInfo><title>New onset of diabetes mellitus with ziprasidone: A case report</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Sanchez‐Barranco P. New onset of diabetes mellitus with ziprasidone: A case report. J Clin Psychiatry (2005); 66: 268.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>66</number></detail><extent unit="pages"><start>268</start></extent></part><relatedItem type="host"><titleInfo><title>J Clin Psychiatry</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>66</number></detail><extent unit="pages"><start>268</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit213"><titleInfo><title>Impairing effects of chronic haloperidol and clozapine treatment on recognition memory: Possible relation to oxidative stress (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Schroder N, De Lima MNM, Quevedo J, Pizzol FD, Roesler R. Impairing effects of chronic haloperidol and clozapine treatment on recognition memory: Possible relation to oxidative stress (Letter). Schizophr Res (2005); 73: 377.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>73</number></detail><extent unit="pages"><start>377</start></extent></part><relatedItem type="host"><titleInfo><title>Schizophr Res</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>73</number></detail><extent unit="pages"><start>377</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit214"><titleInfo><title>Promethazine adverse events after implementation of a medication shortage interchange</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Sheth HS, Verrico MM, Skledar SJ, Towers AL. Promethazine adverse events after implementation of a medication shortage interchange. Ann Pharmacother (2005); 39: 255.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>255</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Pharmacother</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>255</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit215"><titleInfo><title>Drug‐induced lithium intoxication: A case report (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Spinewine A, Schoevaerdts D, Mwenge GB, Swine C, Dive A. Drug‐induced lithium intoxication: A case report (Letter). J Am Geriatr Soc (2005); 53: 360.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>53</number></detail><extent unit="pages"><start>360</start></extent></part><relatedItem type="host"><titleInfo><title>J Am Geriatr Soc</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>53</number></detail><extent unit="pages"><start>360</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit216"><titleInfo><title>Amitriptyline or not, that is the question: Pharmacogenetic testing of CYP2D6 and CYP219 identifies patients with low or high risk for side effects in amitriptyline therapy</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Steimer W, Zopf K, Von Amelunxen S, Pfeiffer H, Bachofer J, Popp J, Messner B, Kissling W, Leucht S. Amitriptyline or not, that is the question: Pharmacogenetic testing of CYP2D6 and CYP219 identifies patients with low or high risk for side effects in amitriptyline therapy. Clin Chem (YR); 51: 376.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>51</number></detail><extent unit="pages"><start>376</start></extent></part><relatedItem type="host"><titleInfo><title>Clin Chem</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>51</number></detail><extent unit="pages"><start>376</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit217"><titleInfo><title>A 5‐year prospective assessment of the risk associated with individual benzodiazepines and doses in new elderly users</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Tamblyn R, Abrahamowicz M, Du Berger R, McLeod P, Bartlett G. A 5‐year prospective assessment of the risk associated with individual benzodiazepines and doses in new elderly users. J Am Geriatr Soc (2005); 53: 233.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>53</number></detail><extent unit="pages"><start>233</start></extent></part><relatedItem type="host"><titleInfo><title>J Am Geriatr Soc</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>53</number></detail><extent unit="pages"><start>233</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit218"><titleInfo><title>Psychotropic drugs, torsade de pointes and sudden death (Editorial)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Taylor D. Psychotropic drugs, torsade de pointes and sudden death (Editorial). Acta Psychiatr Scand (2005); 111: 169.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>111</number></detail><extent unit="pages"><start>169</start></extent></part><relatedItem type="host"><titleInfo><title>Acta Psychiatr Scand</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>111</number></detail><extent unit="pages"><start>169</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit219"><titleInfo><title>Pisa syndrome in a cohort of Alzheimer's disease patients</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Vanacore N, Suzzareddu G, Maggini M, Casula A, Capelli P, Raschetti R. Pisa syndrome in a cohort of Alzheimer's disease patients. Acta Neurol Scand (2005); 111: 199.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>111</number></detail><extent unit="pages"><start>199</start></extent></part><relatedItem type="host"><titleInfo><title>Acta Neurol Scand</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>111</number></detail><extent unit="pages"><start>199</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit220"><titleInfo><title>Newer antipsychotic drugs and obesity in children and adolescents. How should we assess drug associated weight gain?</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Vieweg WVR, Sood AB, Pandurangi A, Silverman JJ. Newer antipsychotic drugs and obesity in children and adolescents. How should we assess drug associated weight gain?. Acta Psychiatr Scand (2005); 111: 177.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>111</number></detail><extent unit="pages"><start>177</start></extent></part><relatedItem type="host"><titleInfo><title>Acta Psychiatr Scand</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>111</number></detail><extent unit="pages"><start>177</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit221"><titleInfo><title>Cerebrovascular events after treatment of dementia patients with risperidone (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Wancata J. Cerebrovascular events after treatment of dementia patients with risperidone (Letter). Int Psychogeriatr (2004); 16: 493.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>493</start></extent></part><relatedItem type="host"><titleInfo><title>Int Psychogeriatr</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>493</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit222"><titleInfo><title>Blood pressure changes associated with medication treatment of adults with attention‐deficit/hyperactivity disorder</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Wilens TE, Hammerness PG, Biederman J, Kwon A, Spencer TJ, Clark S, Scott M, Podolski A, Ditterline JW, Morris MC, Moore H. Blood pressure changes associated with medication treatment of adults with attention‐deficit/hyperactivity disorder. J Clin Psychiatry (2005); 66: 253.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>66</number></detail><extent unit="pages"><start>253</start></extent></part><relatedItem type="host"><titleInfo><title>J Clin Psychiatry</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>66</number></detail><extent unit="pages"><start>253</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit223"><titleInfo><title>Escitalopram intoxication (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Yuksel FV, Tuzer V, Goka E. Escitalopram intoxication (Letter). Eur Psychiatry (2005); 20: 82.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><extent unit="pages"><start>82</start></extent></part><relatedItem type="host"><titleInfo><title>Eur Psychiatry</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><extent unit="pages"><start>82</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit224"><titleInfo><title>Efficacy and safety of eszopiclone across 6‐weeks of treatment for primary insomnia</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Zammit GK, McNabb LJ, Caron J, Amato DA, Roth T. Efficacy and safety of eszopiclone across 6‐weeks of treatment for primary insomnia. Curr Med Res Opin (2004); 20: 1979.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><extent unit="pages"><start>1979</start></extent></part><relatedItem type="host"><titleInfo><title>Curr Med Res Opin</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><extent unit="pages"><start>1979</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit225"><titleInfo><title>8. Anti‐neoplastic Agents</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit226"><titleInfo><title>Common etiology of capecitabine and fluorouracil‐induced coronary vasospasm in a colon cancer patient (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Aksoy S, Karaca B, Dincer M, Yalcin S. Common etiology of capecitabine and fluorouracil‐induced coronary vasospasm in a colon cancer patient (Letter). Ann Pharmacother (2005); 39: 573.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>573</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Pharmacother</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>573</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit227"><titleInfo><title>Coronary artery spasm induced by 5‐fluorouracil (Case Report) (German)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Alter P, Herzum M, Schaefer JR, Maisch B. Coronary artery spasm induced by 5‐fluorouracil (Case Report) (German). Z Kardiol (2005); 94: 33.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>94</number></detail><extent unit="pages"><start>33</start></extent></part><relatedItem type="host"><titleInfo><title>Z Kardiol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>94</number></detail><extent unit="pages"><start>33</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit228"><titleInfo><title>Topotecan induced nail pigmentation (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Baykal Y, Baykal C, Ozer S, Tulunay G. Topotecan induced nail pigmentation (Letter). J Dermatol (2004); 31: 951.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>31</number></detail><extent unit="pages"><start>951</start></extent></part><relatedItem type="host"><titleInfo><title>J Dermatol</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>31</number></detail><extent unit="pages"><start>951</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit229"><titleInfo><title>High‐dose ifosfamide in relapsed pediatric osteosarcoma: Therapeutic effects and renal toxicity</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Berrak SG, Pearson M, Berberoglu S, Ilhan IE, Jaffe N. High‐dose ifosfamide in relapsed pediatric osteosarcoma: Therapeutic effects and renal toxicity. Pediatr Blood Cancer (2005); 44: 215.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>44</number></detail><extent unit="pages"><start>215</start></extent></part><relatedItem type="host"><titleInfo><title>Pediatr Blood Cancer</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>44</number></detail><extent unit="pages"><start>215</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit230"><titleInfo><title>Population pharmacokinetics of CCI‐779: Correlations to safety and pharmacogenomic responses in patients with advanced renal cancer</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Boni JP, Leister C, Bender G, Fitzpatrick V, Twine N, Stover J, Dorner A, Immermann F, Burczynski ME. Population pharmacokinetics of CCI‐779: Correlations to safety and pharmacogenomic responses in patients with advanced renal cancer. Clin Pharmacol Ther (2005); 77: 76.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>77</number></detail><extent unit="pages"><start>76</start></extent></part><relatedItem type="host"><titleInfo><title>Clin Pharmacol Ther</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>77</number></detail><extent unit="pages"><start>76</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit231"><titleInfo><title>Osteonecrosis: A treatment related toxicity in childhood acute lymphoblastic leukemia (ALL) ‐ Experiences from trial ALL‐BFM 95</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Burger B, Beier R, Zimmermann M, Beck JD, Reiter A, Schrappe M. Osteonecrosis: A treatment related toxicity in childhood acute lymphoblastic leukemia (ALL) ‐ Experiences from trial ALL‐BFM 95. Pediatr Blood Cancer (2005); 44: 220.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>44</number></detail><extent unit="pages"><start>220</start></extent></part><relatedItem type="host"><titleInfo><title>Pediatr Blood Cancer</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>44</number></detail><extent unit="pages"><start>220</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit232"><titleInfo><title>UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Carlini LE, Meropol NJ, Bever J, Andria ML, Hill T, Gold P, Rogatko A, Wang H, Blanchard RL. UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res (2005); 11: 1226.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>11</number></detail><extent unit="pages"><start>1226</start></extent></part><relatedItem type="host"><titleInfo><title>Clin Cancer Res</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>11</number></detail><extent unit="pages"><start>1226</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit233"><titleInfo><title>Oral oncochemotherapies: Side effects‐therapeutic strategy (French)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Delfieu D. Oral oncochemotherapies: Side effects‐therapeutic strategy (French). Pathol Biol (2005); 53: 55.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>53</number></detail><extent unit="pages"><start>55</start></extent></part><relatedItem type="host"><titleInfo><title>Pathol Biol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>53</number></detail><extent unit="pages"><start>55</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit234"><titleInfo><title>Cytarabine‐induced fever complicating the clinical course of leukemia</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Gonen C, Celik I, Cetinkaya YS, Haznedaroglu I. Cytarabine‐induced fever complicating the clinical course of leukemia. Anticancer Drugs (2005); 16: 59.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>59</start></extent></part><relatedItem type="host"><titleInfo><title>Anticancer Drugs</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>59</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit235"><titleInfo><title>Efficacy and safety of tositumomab and iodine‐131 tositumomab (Bexxar) in B‐Cell lymphoma, progressive after rituximab</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Horning SJ, Younes A, Jain V, Kroll S, Lucas J, Podoloff D, Goris M. Efficacy and safety of tositumomab and iodine‐131 tositumomab (Bexxar) in B‐Cell lymphoma, progressive after rituximab. J Clin Oncol (2005); 23: 712.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><extent unit="pages"><start>712</start></extent></part><relatedItem type="host"><titleInfo><title>J Clin Oncol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><extent unit="pages"><start>712</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit236"><titleInfo><title>Granulocyte‐colony‐stimulating factor (filgrastim) may overcome imatinib‐induced neutropenia in patients with chronic‐phase myelogenous leukemia (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Jorgensen HG, Copland M, Holyoake TL. Granulocyte‐colony‐stimulating factor (filgrastim) may overcome imatinib‐induced neutropenia in patients with chronic‐phase myelogenous leukemia (Letter). Cancer (2005); 103: 210.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>103</number></detail><extent unit="pages"><start>210</start></extent></part><relatedItem type="host"><titleInfo><title>Cancer</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>103</number></detail><extent unit="pages"><start>210</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit237"><titleInfo><title>Docetaxel‐induced radiation recall dermatitis (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kandemir EG, Karabudak O, Maydagli A. Docetaxel‐induced radiation recall dermatitis (Letter). Swiss Med Wkly (2005); 135: 34.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>135</number></detail><extent unit="pages"><start>34</start></extent></part><relatedItem type="host"><titleInfo><title>Swiss Med Wkly</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>135</number></detail><extent unit="pages"><start>34</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit238"><titleInfo><title>Safety, pharmacokinetics, immunogenicity, and biodistribution of 186Re‐labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with early‐stage breast cancer</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Koppe M, Van Schaijk F, Roos J, Van Leeuwen P, Heider KH, Kuthan H, Bleichrodt R. Safety, pharmacokinetics, immunogenicity, and biodistribution of 186Re‐labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with early‐stage breast cancer. Cancer Biother Radiopharm (2004); 19: 720.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>19</number></detail><extent unit="pages"><start>720</start></extent></part><relatedItem type="host"><titleInfo><title>Cancer Biother Radiopharm</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>19</number></detail><extent unit="pages"><start>720</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit239"><titleInfo><title>Cone damage in patients receiving high‐dose irofulven treatment</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Lee MS, Gupta N, Penson RT, Loewenstein J, Wepner MS, Seiden MV, Milam AH. Cone damage in patients receiving high‐dose irofulven treatment. Arch Ophthalmol (2005); 123: 29.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>123</number></detail><extent unit="pages"><start>29</start></extent></part><relatedItem type="host"><titleInfo><title>Arch Ophthalmol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>123</number></detail><extent unit="pages"><start>29</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit240"><titleInfo><title>Cardiotoxicity and neurotoxicity of high‐dose continuous fluorouracil as a result of degradation compounds in the drug vials (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Lukaschek J, Nufer M, Maurer D, Asanger M, Honegger H, Widmer L, Malet‐Martino M, Legay R, Martino R. Cardiotoxicity and neurotoxicity of high‐dose continuous fluorouracil as a result of degradation compounds in the drug vials (Letter). J Clin Oncol (2004); 22: 5022.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>22</number></detail><extent unit="pages"><start>5022</start></extent></part><relatedItem type="host"><titleInfo><title>J Clin Oncol</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>22</number></detail><extent unit="pages"><start>5022</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit241"><titleInfo><title>Effect of pre‐transplant cumulative doses of chemotherapeutic drugs on early and long‐term hematological recovery after autologous bone‐marrow transplantation for lymphoma</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Martin A, Perez‐Simon JA, Caballero MD, Lopez‐Holgado N, Vazquez L, Del Canizo MC, San Miguel JF. Effect of pre‐transplant cumulative doses of chemotherapeutic drugs on early and long‐term hematological recovery after autologous bone‐marrow transplantation for lymphoma. Haematologica (YR); 90: 78.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>90</number></detail><extent unit="pages"><start>78</start></extent></part><relatedItem type="host"><titleInfo><title>Haematologica</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>90</number></detail><extent unit="pages"><start>78</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit242"><titleInfo><title>Acceptance of tamoxifen chemoprevention by physicians and women at risk (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">McKay A, Latosinsky S, Martin W. Acceptance of tamoxifen chemoprevention by physicians and women at risk (Letter). Cancer (2005); 103: 209.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>103</number></detail><extent unit="pages"><start>209</start></extent></part><relatedItem type="host"><titleInfo><title>Cancer</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>103</number></detail><extent unit="pages"><start>209</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit243"><titleInfo><title>Third generation aromatase inhibitors may prevent endometrial growth and reverse tamoxifen‐induced uterine changes in postmenopausal breast cancer patients</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Morales L, Timmerman D, Neven P, Konstantinovic ML, Carbonez A, Van Huffel S, Ameye L, Weltens C, Christiaens MR, Vergote I, Paridaens R. Third generation aromatase inhibitors may prevent endometrial growth and reverse tamoxifen‐induced uterine changes in postmenopausal breast cancer patients. Ann Oncol (2005); 16: 70.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>70</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Oncol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>70</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit244"><titleInfo><title>The relationship among lower urinary tract symptoms, prostate specific antigen and erectile dysfunction in men with benign prostatic hyperplasia: Results from the Proscar long‐term efficacy and safety study</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Paick SH, Meehan A, Lee M, Penson DF, Wessells H. The relationship among lower urinary tract symptoms, prostate specific antigen and erectile dysfunction in men with benign prostatic hyperplasia: Results from the Proscar long‐term efficacy and safety study. J Urol (2005); 173: 903.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>173</number></detail><extent unit="pages"><start>903</start></extent></part><relatedItem type="host"><titleInfo><title>J Urol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>173</number></detail><extent unit="pages"><start>903</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit245"><titleInfo><title>Efficacy and safety of recombinant urate oxidase (rasburicase) for treatment and prophylaxis of hyperuricemia in children undergoing chemotherapy</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Pession A, Barbieri E, Santoro N, Paolocci P, Porta F, Locatelli F. Efficacy and safety of recombinant urate oxidase (rasburicase) for treatment and prophylaxis of hyperuricemia in children undergoing chemotherapy. Haematologica (2005); 90: 141.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>90</number></detail><extent unit="pages"><start>141</start></extent></part><relatedItem type="host"><titleInfo><title>Haematologica</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>90</number></detail><extent unit="pages"><start>141</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit246"><titleInfo><title>Dose conversion and cost effectiveness of erythropoietic therapies in chemotherapy‐related anaemia ‐ A meta‐analysis</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Rosberg JH, Ben‐Hamadi R, Cremieux PY, Fastenau JM, Piech CT. Dose conversion and cost effectiveness of erythropoietic therapies in chemotherapy‐related anaemia ‐ A meta‐analysis. Clin Drug Invest (2005); 25: 33.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>33</start></extent></part><relatedItem type="host"><titleInfo><title>Clin Drug Invest</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>33</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit247"><titleInfo><title>Neurological toxicity of long‐term (>1 yr) thalidomide therapy in patients with multiple myeloma</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Tosi P, Zamagni E, Cellini C, Plasmati R, Cangini D, Tacchetti P, Perrone G, Pastorelli F, Tura S, Baccarani M, Cavo M. Neurological toxicity of long‐term (>1 yr) thalidomide therapy in patients with multiple myeloma. Eur J Haematol (2005); 74: 212.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>74</number></detail><extent unit="pages"><start>212</start></extent></part><relatedItem type="host"><titleInfo><title>Eur J Haematol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>74</number></detail><extent unit="pages"><start>212</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit248"><titleInfo><title>A clinical phase I/II trial of rhIL‐4 applied topically in patients with oral squamous cell carcinomas to assess safety and therapeutic activity</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Werkmeister R, Fillies T, Gaertner C, Joos U, Berdel WE. A clinical phase I/II trial of rhIL‐4 applied topically in patients with oral squamous cell carcinomas to assess safety and therapeutic activity. Oncol Rep (2005); 13: 449.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>13</number></detail><extent unit="pages"><start>449</start></extent></part><relatedItem type="host"><titleInfo><title>Oncol Rep</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>13</number></detail><extent unit="pages"><start>449</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit249"><titleInfo><title>9. Haematological Agents</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit250"><titleInfo><title>Efficacy and safety of two doses of enoxaparin in women with thrombophilia and recurrent pregnancy loss: The LIVE‐ENOX study</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Brenner B, Hoffman R, Carp H, Dulitsky M, Younis J. Efficacy and safety of two doses of enoxaparin in women with thrombophilia and recurrent pregnancy loss: The LIVE‐ENOX study. J Thromb Haemost (2005); 3: 227.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>3</number></detail><extent unit="pages"><start>227</start></extent></part><relatedItem type="host"><titleInfo><title>J Thromb Haemost</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>3</number></detail><extent unit="pages"><start>227</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit251"><titleInfo><title>Heparin‐induced thrombocytopenia with acute aortic and renal thrombosis in a patient treated with low‐molecular‐weight heparin</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Chevalier J, Ducasse E, Dasnoy D, Puppinck P. Heparin‐induced thrombocytopenia with acute aortic and renal thrombosis in a patient treated with low‐molecular‐weight heparin. Eur J Vasc Endovasc Surg (2005); 29: 209.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>29</number></detail><extent unit="pages"><start>209</start></extent></part><relatedItem type="host"><titleInfo><title>Eur J Vasc Endovasc Surg</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>29</number></detail><extent unit="pages"><start>209</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit252"><titleInfo><title>Postoperative melagatran/ximelagatran for the prevention of venous thromboembolism following major elective orthopaedic surgery ‐ Effects of timing of first dose and risk factors for thromboembolism and bleeding complications on efficacy and safety</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Dahl OE, Eriksson BI, Agnelli G, Cohen AT, Mouret P, Rosencher N, Panfilov S, Bylock A, Andersson M. Postoperative melagatran/ximelagatran for the prevention of venous thromboembolism following major elective orthopaedic surgery ‐ Effects of timing of first dose and risk factors for thromboembolism and bleeding complications on efficacy and safety. Clin Drug Invest (2005); 25: 65.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>65</start></extent></part><relatedItem type="host"><titleInfo><title>Clin Drug Invest</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>65</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit253"><titleInfo><title>Low‐molecular‐weight heparin‐associated fat necrosis of the breast (Case Report)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Das AK. Low‐molecular‐weight heparin‐associated fat necrosis of the breast (Case Report). Age Ageing (2005); 34: 193.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>34</number></detail><extent unit="pages"><start>193</start></extent></part><relatedItem type="host"><titleInfo><title>Age Ageing</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>34</number></detail><extent unit="pages"><start>193</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit254"><titleInfo><title>Tolerance to intravenous heparin in patients with delayed‐typed hypersensitivity to heparins: A prospective study</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Gaigl Z, Pfeuffer P, Raith P, Brocker EB, Trautmann A. Tolerance to intravenous heparin in patients with delayed‐typed hypersensitivity to heparins: A prospective study. Br J Haematol (2005); 128: 389.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>128</number></detail><extent unit="pages"><start>389</start></extent></part><relatedItem type="host"><titleInfo><title>Br J Haematol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>128</number></detail><extent unit="pages"><start>389</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit255"><titleInfo><title>Enhanced antithrombotic effect of warfarin associated with low‐dose alcohol consumption (Case Report)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Havrda DE, Mai T, Chonlahan J. Enhanced antithrombotic effect of warfarin associated with low‐dose alcohol consumption (Case Report). Pharmacotherapy (2005); 25: 303.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>303</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacotherapy</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>303</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit256"><titleInfo><title>Possible warfarin interaction with menthol cough drops</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kassebaum PJ, Shaw DL, Tomich DJ. Possible warfarin interaction with menthol cough drops. Ann Pharmacother (2005); 39: 365.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>365</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Pharmacother</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>365</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit257"><titleInfo><title>Efficacy and safety of fixed low‐dose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients ‐ A subgroup analysis of the PREVENT trial</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kucher N, Leizorovicz A, Vaitkus PT, Cohen AT, Turpie AGG, Olsson CG, Goldhaber SZ. Efficacy and safety of fixed low‐dose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients ‐ A subgroup analysis of the PREVENT trial. Arch Intern Med (2005); 165: 341.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>165</number></detail><extent unit="pages"><start>341</start></extent></part><relatedItem type="host"><titleInfo><title>Arch Intern Med</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>165</number></detail><extent unit="pages"><start>341</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit258"><titleInfo><title>Intra‐arterial thrombolysis in patients treated with warfarin</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Linfante I, Reddy AS, Andreone V, Caplan LR, Selim M, Hirsch JA. Intra‐arterial thrombolysis in patients treated with warfarin. Cerebrovasc Dis (2005); 19: 133.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>19</number></detail><extent unit="pages"><start>133</start></extent></part><relatedItem type="host"><titleInfo><title>Cerebrovasc Dis</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>19</number></detail><extent unit="pages"><start>133</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit259"><titleInfo><title>Unexpected delayed‐type hypersensitivity skin reactions to the ultra‐low‐molecular‐weight heparin fondaparinux</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Maetzke J, Hinrichs R, Schneider LA, Scharffetter‐Kochanek K. Unexpected delayed‐type hypersensitivity skin reactions to the ultra‐low‐molecular‐weight heparin fondaparinux. Allergy (2005); 60: 413.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>60</number></detail><extent unit="pages"><start>413</start></extent></part><relatedItem type="host"><titleInfo><title>Allergy</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>60</number></detail><extent unit="pages"><start>413</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit260"><titleInfo><title>Retrospective evaluation of a possible interaction between warfarin and levofloxacin</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">McCall KL, Scott JC, Anderson HG. Retrospective evaluation of a possible interaction between warfarin and levofloxacin. Pharmacotherapy (2005); 25: 67.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>67</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacotherapy</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>67</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit261"><titleInfo><title>10. Neuroregulator‐Blocking Agents</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit262"><titleInfo><title>Safety of desloratadine syrup in children</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Bloom M, Staudinger H, Herron J. Safety of desloratadine syrup in children. Curr Med Res Opin (2004); 20: 1959.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><extent unit="pages"><start>1959</start></extent></part><relatedItem type="host"><titleInfo><title>Curr Med Res Opin</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><extent unit="pages"><start>1959</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit263"><titleInfo><title>Cutaneous adverse drug reaction to oral chlorphenamine detected with patch testing</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Brown VL, Orton DI. Cutaneous adverse drug reaction to oral chlorphenamine detected with patch testing. Contact Dermatitis (2005); 52: 49.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>52</number></detail><extent unit="pages"><start>49</start></extent></part><relatedItem type="host"><titleInfo><title>Contact Dermatitis</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>52</number></detail><extent unit="pages"><start>49</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit264"><titleInfo><title>Memantine and progressive glaucoma</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Greenfield DS, Girkin C, Kwon YH. Memantine and progressive glaucoma. J Glaucoma (2005); 14: 84.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>14</number></detail><extent unit="pages"><start>84</start></extent></part><relatedItem type="host"><titleInfo><title>J Glaucoma</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>14</number></detail><extent unit="pages"><start>84</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit265"><titleInfo><title>Metoclopramide‐induced tardive dyskinesia in an infant</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Mejia NI, Jankovic J. Metoclopramide‐induced tardive dyskinesia in an infant. Mov Disord (2005); 20: 86.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><extent unit="pages"><start>86</start></extent></part><relatedItem type="host"><titleInfo><title>Mov Disord</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><extent unit="pages"><start>86</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit266"><titleInfo><title>Liver injury due to potassium para‐aminobenzoate (Potaba®) (Letter) (French)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Mesnil A, Lewden B, Dumortier J, Cuche M, Euvrard P, Dorez D, Vial T. Liver injury due to potassium para‐aminobenzoate (Potaba®) (Letter) (French). Gastroenterol Clin Biol (2004); 28: 1295.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>1295</start></extent></part><relatedItem type="host"><titleInfo><title>Gastroenterol Clin Biol</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>1295</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit267"><titleInfo><title>One‐year multicenter, double‐masked, placebo‐controlled, parallel safety and efficacy study of 2% pirenzepine ophthalmic gel in children with myopia</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Tan DTH, Lam DS, Chua WH, Shu‐Piang DF, Crockett RS. One‐year multicenter, double‐masked, placebo‐controlled, parallel safety and efficacy study of 2% pirenzepine ophthalmic gel in children with myopia. Ophthalmology (2005); 112: 84.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>112</number></detail><extent unit="pages"><start>84</start></extent></part><relatedItem type="host"><titleInfo><title>Ophthalmology</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>112</number></detail><extent unit="pages"><start>84</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit268"><titleInfo><title>Chronic neuropathic pain associated with imiquimod: Report of 2 cases</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Yi BA, Nirenberg M, Goldstein SM, Berger TG. Chronic neuropathic pain associated with imiquimod: Report of 2 cases. J Am Acad Dermatol (2005); 52: S57.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>52</number></detail><extent unit="pages"><start>S57</start></extent></part><relatedItem type="host"><titleInfo><title>J Am Acad Dermatol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>52</number></detail><extent unit="pages"><start>S57</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit269"><titleInfo><title>11. Dermatological Agents</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit270"><titleInfo><title>Affective psychosis following Accutane (isotretinoin) treatment</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Barak Y, Wohl Y, Greenberg Y, Dayan YB, Friedman T, Shoval G, Knobler HY. Affective psychosis following Accutane (isotretinoin) treatment. Int Clin Psychopharmacol (2005); 20: 39.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><extent unit="pages"><start>39</start></extent></part><relatedItem type="host"><titleInfo><title>Int Clin Psychopharmacol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><extent unit="pages"><start>39</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit271"><titleInfo><title>Assessment of the safety and efficacy of poly L‐lactic acid for the treatment of HIV‐associated facial lipotrophy</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Burgess CM, Quiroga RM. Assessment of the safety and efficacy of poly L‐lactic acid for the treatment of HIV‐associated facial lipotrophy. J Am Acad Dermatol (2005); 52: 233.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>52</number></detail><extent unit="pages"><start>233</start></extent></part><relatedItem type="host"><titleInfo><title>J Am Acad Dermatol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>52</number></detail><extent unit="pages"><start>233</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit272"><titleInfo><title>Aphthous ulcers associated with imiquimod and the treatment of actinic cheilitis</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Chakrabarty AK, Mraz S, Geisse MK, Anderson NJ. Aphthous ulcers associated with imiquimod and the treatment of actinic cheilitis. J Am Acad Dermatol (2005); 52: S35.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>52</number></detail><extent unit="pages"><start>S35</start></extent></part><relatedItem type="host"><titleInfo><title>J Am Acad Dermatol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>52</number></detail><extent unit="pages"><start>S35</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit273"><titleInfo><title>Efficacy, safety and acceptability of precipitated sulphur petrolatum for topical treatment of scabies at the city of Coro, Falcon State, Venezuela (Spanish, English Abstract)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Diaz M, Cazorla D, Acosta M. Efficacy, safety and acceptability of precipitated sulphur petrolatum for topical treatment of scabies at the city of Coro, Falcon State, Venezuela (Spanish, English Abstract). Rev Invest Clin (2004); 56: 615.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>56</number></detail><extent unit="pages"><start>615</start></extent></part><relatedItem type="host"><titleInfo><title>Rev Invest Clin</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>56</number></detail><extent unit="pages"><start>615</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit274"><titleInfo><title>Does topical tacrolimus induce lentigines in children with atopic dermatitis? A cases report of three cases</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Hickey JR, Robson A, Barker JNWN, Smith CH. Does topical tacrolimus induce lentigines in children with atopic dermatitis? A cases report of three cases. Brit J Dermatol (2005); 152: 152.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>152</number></detail><extent unit="pages"><start>152</start></extent></part><relatedItem type="host"><titleInfo><title>Brit J Dermatol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>152</number></detail><extent unit="pages"><start>152</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit275"><titleInfo><title>Long‐term treatment of atopic dermatitis with pimecrolimus cream 1% in infants does not interfere with the development of protective antibodies after vaccination</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Papp KA, Breuer K, Meurer M, Ortonne JP, Potter PC, De Prost Y, Davidson MJ, Barbier N, Goertz HP, Paul C. Long‐term treatment of atopic dermatitis with pimecrolimus cream 1% in infants does not interfere with the development of protective antibodies after vaccination. J Am Acad Dermatol (2005); 52: 247.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>52</number></detail><extent unit="pages"><start>247</start></extent></part><relatedItem type="host"><titleInfo><title>J Am Acad Dermatol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>52</number></detail><extent unit="pages"><start>247</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit276"><titleInfo><title>12. Immunosuppressive Agents</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit277"><titleInfo><title>Switching from cyclosporine to tacrolimus in patients with chronic transplant dysfunction or cyclosporine induced adverse events</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Cantarovich D, Renou M, Megnigbeto A, Giral‐Classe M, Hourmant M, Dantal J, Blancho G, Karam G, Soulillou JP. Switching from cyclosporine to tacrolimus in patients with chronic transplant dysfunction or cyclosporine induced adverse events. Transplantation (2005); 79: 72.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>79</number></detail><extent unit="pages"><start>72</start></extent></part><relatedItem type="host"><titleInfo><title>Transplantation</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>79</number></detail><extent unit="pages"><start>72</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit278"><titleInfo><title>De novo thrombotic microangiopathy following treatment with sirolimus: Report of two cases</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Crew RJ, Radhakrishnan J, Cohen DJ, Stern L, Goldstein M, Hardy M, D'Agati VD, Markowitz GS. De novo thrombotic microangiopathy following treatment with sirolimus: Report of two cases. Nephrol Dial Transplant (2005); 20: 203.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><extent unit="pages"><start>203</start></extent></part><relatedItem type="host"><titleInfo><title>Nephrol Dial Transplant</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><extent unit="pages"><start>203</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit279"><titleInfo><title>Infliximab‐induced cerebral thrombophlebitis (Case Report)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Grange L, Nissen MJ, Garambois K, Dumolard A, Duc C, Gaudin P, Juvin R. Infliximab‐induced cerebral thrombophlebitis (Case Report). Rheumatology (2005); 44: 260.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>44</number></detail><extent unit="pages"><start>260</start></extent></part><relatedItem type="host"><titleInfo><title>Rheumatology</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>44</number></detail><extent unit="pages"><start>260</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit280"><titleInfo><title>Assessment of glomerular and tubular functions in renal transplant patients receiving cyclosporine A in combination with either sirolimus or everolimus</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kamar N, Allard J, Ribes D, Durand D, Ader JL, Rostaing L. Assessment of glomerular and tubular functions in renal transplant patients receiving cyclosporine A in combination with either sirolimus or everolimus. Clin Nephrol (2005); 63: 80.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>63</number></detail><extent unit="pages"><start>80</start></extent></part><relatedItem type="host"><titleInfo><title>Clin Nephrol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>63</number></detail><extent unit="pages"><start>80</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit281"><titleInfo><title>Azathioprine‐induced pancytopenia in a patient with pompholyx and deficiency of erythrocyte thiopurine methyltransferase</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Konstantopoulou M, Belgi A, Griffiths KD, Seale JRC, Macfarlane AW. Azathioprine‐induced pancytopenia in a patient with pompholyx and deficiency of erythrocyte thiopurine methyltransferase. Br Med J (2005); 330: 350.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>330</number></detail><extent unit="pages"><start>350</start></extent></part><relatedItem type="host"><titleInfo><title>Br Med J</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>330</number></detail><extent unit="pages"><start>350</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit282"><titleInfo><title>Pharmacokinetic interaction between tacrolimus and clarithromycin in a heart transplant patient (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kunicki PK, Sobieszczanska‐Malek M. Pharmacokinetic interaction between tacrolimus and clarithromycin in a heart transplant patient (Letter). Ther Drug Monit (2005); 27: 107.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>107</start></extent></part><relatedItem type="host"><titleInfo><title>Ther Drug Monit</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>107</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit283"><titleInfo><title>Initial experience with sirolimus and mycophenolate mofetil for renal rescue from cyclosporine nephrotoxicity after heart transplantation</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Lyster H, Panicker G, Leaver N, Banner NR. Initial experience with sirolimus and mycophenolate mofetil for renal rescue from cyclosporine nephrotoxicity after heart transplantation. Transplant Proc (2004); 36: 3167.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>36</number></detail><extent unit="pages"><start>3167</start></extent></part><relatedItem type="host"><titleInfo><title>Transplant Proc</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>36</number></detail><extent unit="pages"><start>3167</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit284"><titleInfo><title>Azathioprine‐induced pancreatitis in Crohn's disease: A smoking gun or guilt by association (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Mardini HE. Azathioprine‐induced pancreatitis in Crohn's disease: A smoking gun or guilt by association (Letter). Aliment Pharmacol Ther (2005); 21: 195.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>21</number></detail><extent unit="pages"><start>195</start></extent></part><relatedItem type="host"><titleInfo><title>Aliment Pharmacol Ther</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>21</number></detail><extent unit="pages"><start>195</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit285"><titleInfo><title>Nephrotoxicity of rapamycin: An emerging problem in clinical medicine (Comment)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Marti HP, Frey FJ. Nephrotoxicity of rapamycin: An emerging problem in clinical medicine (Comment). Nephrol Dial Transplant (2005); 20: 13.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><extent unit="pages"><start>13</start></extent></part><relatedItem type="host"><titleInfo><title>Nephrol Dial Transplant</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><extent unit="pages"><start>13</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit286"><titleInfo><title>Gastrointestinal leukocytoclastic vasculitis: An adverse effect of sirolimus (Case Report)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Nagarajan S, Friedrich T, Garcia M, Kambham N, Sarwal MM. Gastrointestinal leukocytoclastic vasculitis: An adverse effect of sirolimus (Case Report). Pediatr Transplant (2005); 9: 97.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>9</number></detail><extent unit="pages"><start>97</start></extent></part><relatedItem type="host"><titleInfo><title>Pediatr Transplant</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>9</number></detail><extent unit="pages"><start>97</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit287"><titleInfo><title>Multifocal motor neuropathy with conduction block in a patient with rheumatoid arthritis on infliximab therapy (Case Reports)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Rodriguez‐Escalera C, Belzunegui J, Lopez‐Dominguez L, Gonzalez C, Figueroa M. Multifocal motor neuropathy with conduction block in a patient with rheumatoid arthritis on infliximab therapy (Case Reports). Rheumatology (2005); 44: 132.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>44</number></detail><extent unit="pages"><start>132</start></extent></part><relatedItem type="host"><titleInfo><title>Rheumatology</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>44</number></detail><extent unit="pages"><start>132</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit288"><titleInfo><title>Clinical relevance of sirolimus drug interactions in transplant patients</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Sadaba B, Campanero MA, Quetglas EG, Azanza JR. Clinical relevance of sirolimus drug interactions in transplant patients. Transplant Proc (2004); 36: 3226.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>36</number></detail><extent unit="pages"><start>3226</start></extent></part><relatedItem type="host"><titleInfo><title>Transplant Proc</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>36</number></detail><extent unit="pages"><start>3226</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit289"><titleInfo><title>Long‐term open‐label preliminary study of the safety and efficacy of leflunomide in patients with polyarticular‐course juvenile rheumatoid arthritis</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Silverman E, Spiegel L, Hawkins D, Petty R, Goldsmith D, Schanberg L, Duffy C, Howard P, Strand V. Long‐term open‐label preliminary study of the safety and efficacy of leflunomide in patients with polyarticular‐course juvenile rheumatoid arthritis. Arthritis Rheum (2005); 52: 554.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>52</number></detail><extent unit="pages"><start>554</start></extent></part><relatedItem type="host"><titleInfo><title>Arthritis Rheum</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>52</number></detail><extent unit="pages"><start>554</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit290"><titleInfo><title>Post‐coronary artery bypass graft liver failure: A possible association with leflunomide</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Thomasset SC, Ong SL, Large SR. Post‐coronary artery bypass graft liver failure: A possible association with leflunomide. Ann Thorac Surg (2005); 79: 698.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>79</number></detail><extent unit="pages"><start>698</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Thorac Surg</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>79</number></detail><extent unit="pages"><start>698</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit291"><titleInfo><title>Efficacy and safety of infliximab in patients with ankylosing spondylitis ‐ Results of a randomized, placebo‐controlled trial (ASSERT)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, Braun K. Efficacy and safety of infliximab in patients with ankylosing spondylitis ‐ Results of a randomized, placebo‐controlled trial (ASSERT). Arthritis Rheum (2005); 52: 582.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>52</number></detail><extent unit="pages"><start>582</start></extent></part><relatedItem type="host"><titleInfo><title>Arthritis Rheum</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>52</number></detail><extent unit="pages"><start>582</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit292"><titleInfo><title>13. Autonomic Agents</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit293"><titleInfo><title>Ephedrine‐ and guaifenesin‐induced nephrolithiasis</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Bennett S, Hoffman N, Monga M. Ephedrine‐ and guaifenesin‐induced nephrolithiasis. J Altern Complement Med (2004); 10: 967.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>10</number></detail><extent unit="pages"><start>967</start></extent></part><relatedItem type="host"><titleInfo><title>J Altern Complement Med</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>10</number></detail><extent unit="pages"><start>967</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit294"><titleInfo><title>An open‐label evaluation of the tolerability and safety of Stavelo® (carbidopa, levodopa and entacapone) in Parkinson's disease patients experiencing wearing‐off</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Koller W, Guarnieri M, Hubble J, Rabinowicz AL, Silver D. An open‐label evaluation of the tolerability and safety of Stavelo® (carbidopa, levodopa and entacapone) in Parkinson's disease patients experiencing wearing‐off. J Neural Transm (2005); 112: 221.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>112</number></detail><extent unit="pages"><start>221</start></extent></part><relatedItem type="host"><titleInfo><title>J Neural Transm</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>112</number></detail><extent unit="pages"><start>221</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit295"><titleInfo><title>Prolongation of QT interval by terbutaline in healthy subjects</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kuusela TA, Jartti TT, Tahvanainen KUO, Kaila TJ. Prolongation of QT interval by terbutaline in healthy subjects. J Cardiovasc Pharmacol (2005); 45: 175.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>45</number></detail><extent unit="pages"><start>175</start></extent></part><relatedItem type="host"><titleInfo><title>J Cardiovasc Pharmacol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>45</number></detail><extent unit="pages"><start>175</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit296"><titleInfo><title>Blue digits: Cyanosis resulting from norepinephrine treatment</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">McAllister SF, Cleary JD. Blue digits: Cyanosis resulting from norepinephrine treatment. Ann Pharmacother (2005); 39: 383.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>383</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Pharmacother</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>383</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit297"><titleInfo><title>Cardiovascular safety of tamsulosin modified release in the fasted and fed state in elderly healthy subjects</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Michel MC, Korstanje C, Krauwinkel W. Cardiovascular safety of tamsulosin modified release in the fasted and fed state in elderly healthy subjects. Eur Urol Suppl (2005); 4: 9.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>4</number></detail><extent unit="pages"><start>9</start></extent></part><relatedItem type="host"><titleInfo><title>Eur Urol Suppl</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>4</number></detail><extent unit="pages"><start>9</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit298"><titleInfo><title>Cardiovascular safety of the oral controlled absorption system (OCAS) formulation of tamsulosin compared to the modified release (MR) formulation</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Michel MC, Korstanje C, Klauwinkel W, Shear M, Davies J, Quartel A. Cardiovascular safety of the oral controlled absorption system (OCAS) formulation of tamsulosin compared to the modified release (MR) formulation. Eur Urol Suppl (2005); 4: 53.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>4</number></detail><extent unit="pages"><start>53</start></extent></part><relatedItem type="host"><titleInfo><title>Eur Urol Suppl</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>4</number></detail><extent unit="pages"><start>53</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit299"><titleInfo><title>Sleep episodes and daytime somnolence as result of individual susceptibility to different dopaminergic drugs in a PD patient: A polysomnographic study</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Romigi A, Brusa L, Marciani MG, Pierantozzi M, Placidi F, Izzi F, Sperli F, Testa F, Stanzione P. Sleep episodes and daytime somnolence as result of individual susceptibility to different dopaminergic drugs in a PD patient: A polysomnographic study. J Neurol Sci (2005); 228: 7.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>228</number></detail><extent unit="pages"><start>7</start></extent></part><relatedItem type="host"><titleInfo><title>J Neurol Sci</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>228</number></detail><extent unit="pages"><start>7</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit300"><titleInfo><title>Suspected β‐antagonist‐induced thrombocytopenia (Case Report)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Stamm PL, Jenkins JK, Vigrass HG. Suspected β‐antagonist‐induced thrombocytopenia (Case Report). Ann Pharmacother (2005); 39: 555.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>555</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Pharmacother</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>555</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit301"><titleInfo><title>14. Respiratory System Agents</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit302"><titleInfo><title>Cataract and ocular hypertension in children on inhaled corticosteroid therapy</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Behbehani AH, Owayed AE, Hijazi ZM, Eslah EA, Al‐Jazzaf AM. Cataract and ocular hypertension in children on inhaled corticosteroid therapy. J Pediatr Ophthalmol Strabismus (2005); 42: 23.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>42</number></detail><extent unit="pages"><start>23</start></extent></part><relatedItem type="host"><titleInfo><title>J Pediatr Ophthalmol Strabismus</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>42</number></detail><extent unit="pages"><start>23</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit303"><titleInfo><title>Efficacy and safety of salmeterol/fluticasone propionate combination delivered by the Diskus™ or pressurised metered‐dose inhaler in children with asthma</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Bracamonte T, Schauer U, Emeryk A, Godwood A, Balsara S. Efficacy and safety of salmeterol/fluticasone propionate combination delivered by the Diskus™ or pressurised metered‐dose inhaler in children with asthma. Clin Drug Invest (2005); 25: 1.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>1</start></extent></part><relatedItem type="host"><titleInfo><title>Clin Drug Invest</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>1</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit304"><titleInfo><title>Reconsidering the safety of over‐the‐counter decongestants</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Caravati EM. Reconsidering the safety of over‐the‐counter decongestants. Ann Emerg Med (2005); 45: 217.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>45</number></detail><extent unit="pages"><start>217</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Emerg Med</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>45</number></detail><extent unit="pages"><start>217</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit305"><titleInfo><title>Albuterol‐induced myocardial ischemia in sickle cell anemia after hemolysis from ceftriaxone administration</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Corso M, Ravindranath TM. Albuterol‐induced myocardial ischemia in sickle cell anemia after hemolysis from ceftriaxone administration. Pediatr Emerg Care (2005); 21: 99.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>21</number></detail><extent unit="pages"><start>99</start></extent></part><relatedItem type="host"><titleInfo><title>Pediatr Emerg Care</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>21</number></detail><extent unit="pages"><start>99</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit306"><titleInfo><title>Are there ocular effects of inhaled steroid therapy? (Editorial)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Nelson LB. Are there ocular effects of inhaled steroid therapy? (Editorial). J Pediatr Ophthalmol Strabismus (2005); 42: 12.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>42</number></detail><extent unit="pages"><start>12</start></extent></part><relatedItem type="host"><titleInfo><title>J Pediatr Ophthalmol Strabismus</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>42</number></detail><extent unit="pages"><start>12</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit307"><titleInfo><title>Long‐term safety of once‐daily budesonide in patients with early‐onset mild persistent asthma: Results of the Inhaled Steroid Treatment as Regular Therapy in Early Asthma (START) study</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Sheffer AL, Silverman M, Woolcock AJ, Diaz PV, Lindberg B, Lindmark B. Long‐term safety of once‐daily budesonide in patients with early‐onset mild persistent asthma: Results of the Inhaled Steroid Treatment as Regular Therapy in Early Asthma (START) study. Ann Allergy Asthma Immunol (YR); 94: 48.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>94</number></detail><extent unit="pages"><start>48</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Allergy Asthma Immunol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>94</number></detail><extent unit="pages"><start>48</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit308"><titleInfo><title>Prescribing for osteoporosis following the use of inhaled and oral glucocorticoids in general practice</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Williams D, Bennett K, Feely J. Prescribing for osteoporosis following the use of inhaled and oral glucocorticoids in general practice. Br J Clin Pharmacol (2004); 58: 665.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>58</number></detail><extent unit="pages"><start>665</start></extent></part><relatedItem type="host"><titleInfo><title>Br J Clin Pharmacol</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>58</number></detail><extent unit="pages"><start>665</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit309"><titleInfo><title>15. Neuromuscular Agents</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit310"><titleInfo><title>Long‐term safety, efficacy, dosing, and development of resistance with botulinum toxin type B in cervical dystonia</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Berman B, Seeberger L, Kumar R. Long‐term safety, efficacy, dosing, and development of resistance with botulinum toxin type B in cervical dystonia. Mov Disord (2005); 20: 233.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><extent unit="pages"><start>233</start></extent></part><relatedItem type="host"><titleInfo><title>Mov Disord</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><extent unit="pages"><start>233</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit311"><titleInfo><title>Safety of succinylcholine in myasthenia gravis (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Levitan R. Safety of succinylcholine in myasthenia gravis (Letter). Ann Emerg Med (2005); 45: 225.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>45</number></detail><extent unit="pages"><start>225</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Emerg Med</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>45</number></detail><extent unit="pages"><start>225</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit312"><titleInfo><title>Cisatracurium‐induced neuromuscular blockade is affected by chronic phenytoin or carbamazepine treatment in neurosurgical patients</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Richard A, Girard F, Girard DC, Boudreault D, Chouinard P, Moumdjian R, Bouthilier A, Ruel M, Couture J, Varin F. Cisatracurium‐induced neuromuscular blockade is affected by chronic phenytoin or carbamazepine treatment in neurosurgical patients. Anesth Analg (2005); 100: 538.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>100</number></detail><extent unit="pages"><start>538</start></extent></part><relatedItem type="host"><titleInfo><title>Anesth Analg</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>100</number></detail><extent unit="pages"><start>538</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit313"><titleInfo><title>16. Reproductive System Agents</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit314"><titleInfo><title>Reversible postpartum cerebral angiopathy associated with bromocriptine therapy (French, English Abstract)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Barroso B, Bigou P, Martin K, Lippa A, Chabouni L, Dakar A, Larribau E, Larrieu JM. Reversible postpartum cerebral angiopathy associated with bromocriptine therapy (French, English Abstract). Rev Neurol (Paris) (2004); 160: 1191.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>160</number></detail><extent unit="pages"><start>1191</start></extent></part><relatedItem type="host"><titleInfo><title>Rev Neurol (Paris)</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>160</number></detail><extent unit="pages"><start>1191</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit315"><titleInfo><title>Association between hormone replacement therapy and subsequent stroke: A meta‐analysis</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Bath PMW, Gray LJ. Association between hormone replacement therapy and subsequent stroke: A meta‐analysis. Br Med J (2005); 330: 342.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>330</number></detail><extent unit="pages"><start>342</start></extent></part><relatedItem type="host"><titleInfo><title>Br Med J</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>330</number></detail><extent unit="pages"><start>342</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit316"><titleInfo><title>Acceptability and side‐effects of Implanon in Switzerland: A retrospective study by the Implanon Swiss Study Group</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Bitzer J, Tschudin S, Alder J. Acceptability and side‐effects of Implanon in Switzerland: A retrospective study by the Implanon Swiss Study Group. Eur J Contracept Reprod Health Care (2004); 9: 278.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>9</number></detail><extent unit="pages"><start>278</start></extent></part><relatedItem type="host"><titleInfo><title>Eur J Contracept Reprod Health Care</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>9</number></detail><extent unit="pages"><start>278</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit317"><titleInfo><title>Commentary: Time to review all the evidence for hormone replacement therapy (Comment)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Crawford F, Langhorne P. Commentary: Time to review all the evidence for hormone replacement therapy (Comment). Br Med J (2005); 330: 345.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>330</number></detail><extent unit="pages"><start>345</start></extent></part><relatedItem type="host"><titleInfo><title>Br Med J</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>330</number></detail><extent unit="pages"><start>345</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit318"><titleInfo><title>The role of leuprolide acetate therapy in triggering auto‐immune thyroiditis (Reply)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Eyal O, Rose SR. The role of leuprolide acetate therapy in triggering auto‐immune thyroiditis (Reply). J Pediatr (2005); 146: 294.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>146</number></detail><extent unit="pages"><start>294</start></extent></part><relatedItem type="host"><titleInfo><title>J Pediatr</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>146</number></detail><extent unit="pages"><start>294</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit319"><titleInfo><title>The role of leuprolide acetate therapy in triggering auto‐immune thyroiditis (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Haller M, Schatz D. The role of leuprolide acetate therapy in triggering auto‐immune thyroiditis (Letter). J Pediatr (2005); 146: 294.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>146</number></detail><extent unit="pages"><start>294</start></extent></part><relatedItem type="host"><titleInfo><title>J Pediatr</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>146</number></detail><extent unit="pages"><start>294</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit320"><titleInfo><title>Potential impact of oral contraceptive choice on myocardial infarction mortality and deep vein thrombosis</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Martin K, Moride Y, Metge C, Moore N, Begaud B. Potential impact of oral contraceptive choice on myocardial infarction mortality and deep vein thrombosis. J Fam Plan Reprod Health Care (2005); 31: 37.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>31</number></detail><extent unit="pages"><start>37</start></extent></part><relatedItem type="host"><titleInfo><title>J Fam Plan Reprod Health Care</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>31</number></detail><extent unit="pages"><start>37</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit321"><titleInfo><title>Safety and efficacy of testosterone gel 1% augmentation in depressed men with partial response to antidepressant therapy</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Orengo CA, Fullerton L, Kunik ME. Safety and efficacy of testosterone gel 1% augmentation in depressed men with partial response to antidepressant therapy. J Geriatr Psychiatry Neurol (2005); 18: 20.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>20</start></extent></part><relatedItem type="host"><titleInfo><title>J Geriatr Psychiatry Neurol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>20</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit322"><titleInfo><title>Effect of multiple‐dose dexloxiglumide on the pharmacokinetics of oral contraceptives in healthy women</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Roy P, Jakate AS, Patel A, Abramowitz W, Wangsa J, Persiani S, Kapil R. Effect of multiple‐dose dexloxiglumide on the pharmacokinetics of oral contraceptives in healthy women. J Clin Pharmacol (2005); 45: 329.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>45</number></detail><extent unit="pages"><start>329</start></extent></part><relatedItem type="host"><titleInfo><title>J Clin Pharmacol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>45</number></detail><extent unit="pages"><start>329</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit323"><titleInfo><title>17. Gastrointestinal System Agents</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit324"><titleInfo><title>Pantoprazole in severe acid‐peptic disease: The effectiveness and safety of 5 years' continuous treatment</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Bardhan KD, Bishop AE, Polak JM, Romanska HM, Rowland A, Thompson M, Morris P, Schaefer‐Preuss S, Luehmann R, McCaldin B. Pantoprazole in severe acid‐peptic disease: The effectiveness and safety of 5 years' continuous treatment. Dig Liver Dis (2005); 37: 10.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>37</number></detail><extent unit="pages"><start>10</start></extent></part><relatedItem type="host"><titleInfo><title>Dig Liver Dis</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>37</number></detail><extent unit="pages"><start>10</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit325"><titleInfo><title>Rabeprazole‐induced acute interstitial nephritis</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Geevasinga N, Coleman PL, Roger SD. Rabeprazole‐induced acute interstitial nephritis. Nephrology (2005); 10: 7.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>10</number></detail><extent unit="pages"><start>7</start></extent></part><relatedItem type="host"><titleInfo><title>Nephrology</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>10</number></detail><extent unit="pages"><start>7</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit326"><titleInfo><title>Community‐acquired pneumonia and use of gastric acid‐suppressive drugs (Reply)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Laheij RJF, Sturkenboom MCJM, Dieleman J, Stricker BHC, Jansen JBMJ. Community‐acquired pneumonia and use of gastric acid‐suppressive drugs (Reply). JAMA (2005); 293: 796.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>293</number></detail><extent unit="pages"><start>796</start></extent></part><relatedItem type="host"><titleInfo><title>JAMA</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>293</number></detail><extent unit="pages"><start>796</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit327"><titleInfo><title>Community‐acquired pneumonia and use of gastric acid‐suppressive drugs (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Sataloff RT. Community‐acquired pneumonia and use of gastric acid‐suppressive drugs (Letter). JAMA (2005); 293: 795.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>293</number></detail><extent unit="pages"><start>795</start></extent></part><relatedItem type="host"><titleInfo><title>JAMA</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>293</number></detail><extent unit="pages"><start>795</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit328"><titleInfo><title>Constipation, laxative use and risk of colorectal cancer: The Miyagi Cohort Study</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Watanabe T, Nakaya N, Kurashima K, Kuriyama S, Tsubono Y, Tsuji I. Constipation, laxative use and risk of colorectal cancer: The Miyagi Cohort Study. Eur J Cancer (2004); 40: 2109.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>40</number></detail><extent unit="pages"><start>2109</start></extent></part><relatedItem type="host"><titleInfo><title>Eur J Cancer</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>40</number></detail><extent unit="pages"><start>2109</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit329"><titleInfo><title>18. Anti‐inflammatory Agents ‐ Steroidal</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit330"><titleInfo><title>Presumed sterile endophthalmitis following intravitreal triamcinolone acetonide injection</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Moshfeghi DM, Kaiser PK, Bakri SJ, Kaiser RS, Maturi RK, Sears JE, Scott IU, Belmont J, Beer PM, Quiroz‐Mercado H, Mieler WF. Presumed sterile endophthalmitis following intravitreal triamcinolone acetonide injection. Ophthalmic Surg Lasers Imaging (2005); 36: 24.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>36</number></detail><extent unit="pages"><start>24</start></extent></part><relatedItem type="host"><titleInfo><title>Ophthalmic Surg Lasers Imaging</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>36</number></detail><extent unit="pages"><start>24</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit331"><titleInfo><title>19. Teratogens/fetal exposure</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit332"><titleInfo><title>The safety of proton pump inhibitors in pregnancy: A multicentre prospective controlled study</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Diav‐Citrin O, Arnon J, Shechtman S, Schaefer C, Tonningen MR, Clementi M, Santis M, Robert‐Gnansia E, Valti E, Malm H, lOrnoy A. The safety of proton pump inhibitors in pregnancy: A multicentre prospective controlled study. Aliment Pharmacol Ther (2005); 21: 269.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>21</number></detail><extent unit="pages"><start>269</start></extent></part><relatedItem type="host"><titleInfo><title>Aliment Pharmacol Ther</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>21</number></detail><extent unit="pages"><start>269</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit333"><titleInfo><title>Postmarketing surveillance for drug safety in pregnancy: The organization of teratology information services project</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Felix RJ, Jones KL, Johnson KA, McCloskey CA, Chambers CD. Postmarketing surveillance for drug safety in pregnancy: The organization of teratology information services project. Birth Defects Res Part A Clin Mol Teratol (2004); 70: 944.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>70</number></detail><extent unit="pages"><start>944</start></extent></part><relatedItem type="host"><titleInfo><title>Birth Defects Res Part A Clin Mol Teratol</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>70</number></detail><extent unit="pages"><start>944</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit334"><titleInfo><title>Absence of teratogenicity of sirolimus used during early pregnancy in a liver transplant recipient</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Jankowska I, Oldakowska‐Jedynak U, Jabiry‐Zieniewicz Z, Cyganek A, Pawlowska J, Teisseyre M, Kalicinski P, Markiewicz M, Paczek L, Socha J. Absence of teratogenicity of sirolimus used during early pregnancy in a liver transplant recipient. Transplant Proc (2004); 36: 3232.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>36</number></detail><extent unit="pages"><start>3232</start></extent></part><relatedItem type="host"><titleInfo><title>Transplant Proc</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>36</number></detail><extent unit="pages"><start>3232</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit335"><titleInfo><title>Insulin and glyburide therapy: Dosage, severity level of gestational diabetes, and pregnancy outcome</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Langer O, Yogev Y, Xenakis EMJ, Rosenn B. Insulin and glyburide therapy: Dosage, severity level of gestational diabetes, and pregnancy outcome. Am J Obstet Gynecol (2005); 192: 134.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>192</number></detail><extent unit="pages"><start>134</start></extent></part><relatedItem type="host"><titleInfo><title>Am J Obstet Gynecol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>192</number></detail><extent unit="pages"><start>134</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit336"><titleInfo><title>Treatment of 51 pregnancies with danaparoid because of heparin intolerance</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Lindhoff‐Last E, Kreutzenbeck HJ, Magnani HN. Treatment of 51 pregnancies with danaparoid because of heparin intolerance. Thromb Haemost (2005); 93: 63.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>93</number></detail><extent unit="pages"><start>63</start></extent></part><relatedItem type="host"><titleInfo><title>Thromb Haemost</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>93</number></detail><extent unit="pages"><start>63</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit337"><titleInfo><title>Use of inhaled corticosteroids during pregnancy and risk of pregnancy induced hypertension: Nested case‐control study</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Martel MJ, Rey E, Beauchesne MF, Perreault S, Lefebvre G, Forget A, Blais L. Use of inhaled corticosteroids during pregnancy and risk of pregnancy induced hypertension: Nested case‐control study. Br Med J (2005); 330: 230.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>330</number></detail><extent unit="pages"><start>230</start></extent></part><relatedItem type="host"><titleInfo><title>Br Med J</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>330</number></detail><extent unit="pages"><start>230</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit338"><titleInfo><title>Successful pregnancy occuring with interferon‐α therapy in chronic myeloid leukemia (Case Report)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Mesquita MM, Pestana A, Mota A. Successful pregnancy occuring with interferon‐α therapy in chronic myeloid leukemia (Case Report). Acta Obstet Gynecol Scand (2005); 84: 300.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>84</number></detail><extent unit="pages"><start>300</start></extent></part><relatedItem type="host"><titleInfo><title>Acta Obstet Gynecol Scand</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>84</number></detail><extent unit="pages"><start>300</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit339"><titleInfo><title>Pain reactivity in 2‐month‐old infants after prenatal and postnatal serotonin reuptake inhibitor medication exposure</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Oberlander TF, Grunau RE, Fitzgerald C, Papsdorf M, Rurak D, Riggs W. Pain reactivity in 2‐month‐old infants after prenatal and postnatal serotonin reuptake inhibitor medication exposure. Pediatrics (2005); 115: 411.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>115</number></detail><extent unit="pages"><start>411</start></extent></part><relatedItem type="host"><titleInfo><title>Pediatrics</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>115</number></detail><extent unit="pages"><start>411</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit340"><titleInfo><title>Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: A database analysis</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Sanz EJ, De‐las‐Cuevas C, Kiuru A, Bate A, Edwards R. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: A database analysis. Lancet (2005); 365: 482.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>365</number></detail><extent unit="pages"><start>482</start></extent></part><relatedItem type="host"><titleInfo><title>Lancet</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>365</number></detail><extent unit="pages"><start>482</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit341"><titleInfo><title>Cough mixture abuse in pregnancy, folate deficiency, and neural tube defects? (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Tsang SK, Au WY. Cough mixture abuse in pregnancy, folate deficiency, and neural tube defects? (Letter). Am J Hematol (2005); 78: 163.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>78</number></detail><extent unit="pages"><start>163</start></extent></part><relatedItem type="host"><titleInfo><title>Am J Hematol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>78</number></detail><extent unit="pages"><start>163</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit342"><titleInfo><title>Post‐marketing surveillance should include effects during pregnancy? (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Yeargin P. Post‐marketing surveillance should include effects during pregnancy? (Letter). Br Med J (2005); 330: 308.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>330</number></detail><extent unit="pages"><start>308</start></extent></part><relatedItem type="host"><titleInfo><title>Br Med J</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>330</number></detail><extent unit="pages"><start>308</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit343"><titleInfo><title>20. Others</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit344"><titleInfo><title>Troglitazone and liver injury: In search of answers</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Chojkier M. Troglitazone and liver injury: In search of answers. Hepatology (2005); 41: 237.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>41</number></detail><extent unit="pages"><start>237</start></extent></part><relatedItem type="host"><titleInfo><title>Hepatology</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>41</number></detail><extent unit="pages"><start>237</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit345"><titleInfo><title>Tolerability profile of metformin/glibenclamide combination tablets (Glucovance®) A new treatment for the management of type 2 diabetes mellitus</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Davidson JA, Scheen AJ, Howlett HCS. Tolerability profile of metformin/glibenclamide combination tablets (Glucovance®) A new treatment for the management of type 2 diabetes mellitus. Drug Saf (2004); 27: 1205.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>1205</start></extent></part><relatedItem type="host"><titleInfo><title>Drug Saf</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>1205</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit346"><titleInfo><title>Bilateral acute uveitis and conjunctivitis after zoledronic acid therapy (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Durnian JM, Olujohungbe A, Kyle G. Bilateral acute uveitis and conjunctivitis after zoledronic acid therapy (Letter). Eye (2005); 19: 221.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>19</number></detail><extent unit="pages"><start>221</start></extent></part><relatedItem type="host"><titleInfo><title>Eye</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>19</number></detail><extent unit="pages"><start>221</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit347"><titleInfo><title>Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kolterman OG, Kim DD, Shen L, Ruggles JA, Nielsen LL, Fineman MS, Baron AD. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm (2005); 62: 173.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>62</number></detail><extent unit="pages"><start>173</start></extent></part><relatedItem type="host"><titleInfo><title>Am J Health Syst Pharm</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>62</number></detail><extent unit="pages"><start>173</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit348"><titleInfo><title>Rosiglitazone‐induced proptasis</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Levin F, Kazim M, Smith TJ, Marcovici E. Rosiglitazone‐induced proptasis. Arch Ophthalmol (2005); 123: 119.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>123</number></detail><extent unit="pages"><start>119</start></extent></part><relatedItem type="host"><titleInfo><title>Arch Ophthalmol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>123</number></detail><extent unit="pages"><start>119</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit349"><titleInfo><title>Safety of oral iron chelator deferiprone in young thalassaemics</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Naithani R, Chandra J, Sharma S. Safety of oral iron chelator deferiprone in young thalassaemics. Eur J Haematol (2005); 74: 217.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>74</number></detail><extent unit="pages"><start>217</start></extent></part><relatedItem type="host"><titleInfo><title>Eur J Haematol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>74</number></detail><extent unit="pages"><start>217</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit350"><titleInfo><title>Insight into hepatotoxicity: The troglitazone experience (Editorial)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Watkins PB. Insight into hepatotoxicity: The troglitazone experience (Editorial). Hepatology (2005); 41: 229.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>41</number></detail><extent unit="pages"><start>229</start></extent></part><relatedItem type="host"><titleInfo><title>Hepatology</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>41</number></detail><extent unit="pages"><start>229</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit351"><titleInfo><title>Alendronate and risedronate: Reports of severe bone, joint and muscle pain (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Wysowski DK, Chang JT. Alendronate and risedronate: Reports of severe bone, joint and muscle pain (Letter). Arch Intern Med (2005); 165: 346.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>165</number></detail><extent unit="pages"><start>346</start></extent></part><relatedItem type="host"><titleInfo><title>Arch Intern Med</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>165</number></detail><extent unit="pages"><start>346</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit352"><titleInfo><title>Weekly alendronate‐induced acute pseudogout (Case Reports)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Young‐Min SA, Herbert L, Dick M, Fordham J. Weekly alendronate‐induced acute pseudogout (Case Reports). Rheumatology (2005); 44: 131.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>44</number></detail><extent unit="pages"><start>131</start></extent></part><relatedItem type="host"><titleInfo><title>Rheumatology</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>44</number></detail><extent unit="pages"><start>131</start></extent></part></relatedItem></relatedItem><identifier type="istex">2373BA77F1E26EB00479968C030A9652218EB467</identifier><identifier type="ark">ark:/67375/WNG-FRP40FW4-3</identifier><identifier type="DOI">10.1002/pds.1030</identifier><identifier type="ArticleID">PDS1030</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2005 John Wiley & Sons, Ltd.</accessCondition><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-L0C46X92-X">wiley</recordContentSource><recordOrigin>Converted from (version ) to MODS version 3.6.</recordOrigin><recordCreationDate encoding="w3cdtf">2019-11-16</recordCreationDate></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-FRP40FW4-3/record.json</uri></json:item></metadata><author></author><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001B59 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001B59 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:2373BA77F1E26EB00479968C030A9652218EB467
|texte= Current awareness: Pharmacoepidemiology and drug safety
}}
| This area was generated with Dilib version V0.6.33. |  |